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1.1 History
The origins of nuclear medicine can be traced back to the end of the 19th century when 
Henri Becquerel, while working on phosphorescence, discovered that some uranium salts 
spontaneously emit an invisible penetrating radiation, much like the X-rays discovered by 
Wilhelm Conrad Röntgen just a year earlier. A period of intense research into radioactivity 
followed which led to the discovery of additional radioactive elements of thorium, polonium 
and radium. In 1903 Marie Curie, Pierre Curie and Henri Becquerel jointly received the Nobel 
Prize in physics for their work in the field of radioactivity. Their discoveries were the basis for 
the field of nuclear medicine [1][2].
While the electron was discovered already in 1897 by Sir Joseph John Thomson studying 
the properties of cathode rays [3], it took another 35 years until it’s antiparticle, the positron, 
was first described by Carl Anderson as a distinct particle and evidence of antimatter. 
Investigating cosmic ray interactions in a cloud chamber, Anderson found in 1932 that in a 
magnetic field some particle trails were bent similarly to those of the electrons, but in the 
opposite direction. This could only mean a particle with the same mass but opposite charge 
– an antielectron or positron.
Although humanity has always been exposed to ionizing radiation, we have not developed 
any senses for its detection. With the discovery of X-rays and radioactivity, the need arose for 
methods and instruments to detect and study the new phenomenon. Initially photographic 
plates and emulsions were developed that made use of the darkening of the material 
under irradiation. In 1899, thanks to the work of Thomson, the operating characteristics 
of ionization chambers were well understood and consequently used by Marie Curie in her 
investigation into radioactive materials. The first instrument that could detect individual rays 
was the spinthariscope, invented by William Crookes in 1903. The first cloud chamber was 
built in 1911 by Charles Thomson Rees Wilson which in addition to detecting individual rays, 
makes it possible to visualise the path of the ray or particle. In 1928 Hans Geiger and Walther 
Muller introduced the so called Geiger-Muller or GM counter which responded to individual 
radiation-induced events by giving a high level output signal. The GM counter found wide 
use due to its low cost, simplicity and ease of operation. The drawbacks were that it could not 
directly measure the energy of radiation and was limited to relatively low counting rates [4]. 
In 1948, Harmut Kallmann suggested that the scintillations produced when radiation 
interacted with certain types of materials could be individually detected and amplified by 
photomultiplier tubes for electronic counting [5]. This, along with the discovery of calcium 
tungstate by Benedict Cassen, Lawrence Curtis and Clifton Reed as a detector for high energy 
gamma photons, lead to the development of the scintillator detector [6].
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In 1951 Frank Wrenn, Myron Good and Philip Handler proposed a possible use of thallium-
activated sodium iodide (NaI) detectors opposite to each other [7]. From experiments 
comparing single photon and coincidence detection, Wrenn concluded „thus, it appears 
possible to more accurately delimit point sources, and hence extended sources with the 
technique of coincidence counting of annihilation pairs”. Independently working Gordon 
Brownell and William Sweet reported in 1953 on a device designed for localization of brain 
tumours [8]. It had two collinear NaI detectors mounted on an adjustable platform moving 
in a rectilinear fashion and a printer recording the coincidence counting rate. The positron 
scanners developed at the time, although using coincidence detection instead of lead 
collimators, still lacked the required sensitivity. 
In 1961, to improve sensitivity, Rankowitz et al. positioned a complete ring of scintillation 
detectors around the object to be scanned [9]. Still limited by under-sampling and lack of attenuation 
correction, the system demonstrated the advantages of electronic collimation. In 1963, Hal Anger 
and Alexander Gottschalk designed a prototype system capable of imaging an entire brain with 
no mechanical scanning motion or collimators. The authors reported a sensitivity about 20 times 
higher than what was achieved with a collimator system under identical conditions [10].
At the beginning of 1970s, Godfrey Hounsfield and James Ambrose proposed a method 
of using radiograph transmission measurements at multiple angles through the head of a 
patient. A computer would calculate the absorption values and display these as tomographic 
slices [11–13].
In the years 1972 – 1973 Michael Phelps, Edward Hoffman, Nizar Mullani and Michel Ter-
Pogossian from Washington University built a device called PETT II, which used annihilation 
coincidence detection to reconstruct transaxial tomograms [14]. Reconstruction was done 
using the locally developed Fourier-based method instead of the algebraic base method used 
on CT scanners. Attenuation correction measurements were done using a thin plastic ring 
filled with 64Cu placed around the object. In 1975, the prototype was developed into a clinically 
applicable PET (III) whole-body camera for which the sensitivity allowed to perform scanning 
in 2-4 minutes per slice [15]. The PET (III) system was used in Washington University and later 
at Brookhaven National Laboratory for both human and animal studies. 
In the late 1970s and 1980s the single ring of NaI scintillation crystals was expanded to 
multiple rings and NaI replaced with a more suitable bismuth germanate oxide (BGO) [16]. 
The use of BGO represented a major advancement over NaI because the twice higher density 
allowed the use of smaller crystals while having three times the detection efficiency. Another 
type of scintillator crystal, cesium fluoride was also investigated, due to its fast scintillation 
and application in time-of-flight detection schemes [17], leading to the eventual development 
of commercial time-of-flight detectors.
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In 1990s, most systems used BGO crystals and larger axial field of view (>15 cm) with 4-5 mm 
spatial resolution. Also 3D imaging became available by removing the lead septa separating 
the detector rings so all detectors in all planes can register coincidence events [18].
All of the previously mentioned inventions and discoveries have contributed significantly 
to the imaging systems we see in use today. Most recent generation of positron emission 
tomography systems have no photomultiplier tubes and use digital detectors coupled directly to 
scintillator crystals instead, resulting in increased spatial and timing resolution as well as highly 
stable performance across a large dynamic range of count rates [19]. While BGO is still used as a 
scintillator material, new lutetium based fast scintillators are widely utilised to facilitate better 
time-of-flight characteristics of modern PET systems. Axial field of view has increased to >25 cm 
and with it the sensitivity to >22 cps/kBq. A total body scanner is already in development. All 
contemporary PET systems by major vendors are equipped with a combined CT or MR modality 
used for attenuation correction and additional anatomical and functional information.
1.2 Positron emission tomography (PET)
PET is a functional imaging technique in nuclear medicine where radiopharmaceutical is 
administered intravenously to a patient and the behaviour of the substance within the body 
is monitored using specialised imaging equipment. A radiopharmaceutical consists of a 
biologically active molecule, called tracer, and a radionuclide that in case of PET, is a positron 
emitting radioisotope which allows the visualisation of the radiolabelled tracer in a PET system.
Many different tracer molecules have been developed which are used to observe various 
metabolic processes such as glucose metabolism, tumour growth, blood flow, receptor 
expression [20][21][22]. After administration to the patient, the radiolabelled compound 
travels throughout the bloodstream and accumulates based on the biological properties of the 
tracer. In the case of the glucose analogue 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) glucose 
utilising parts of the body. In the patient’s body the nucleus of the radioisotope used as a label 
decays by emitting a positron. The emitted positron travels a small (≤ 3mm, in case of [18F]) 
distance losing its remaining kinetic energy, after which it interacts with an electron, both 
annihilate resulting in two 511 keV photons emitted essentially in opposite directions. A PET 
camera looks for these simultaneously emitted photons and when two are detected within the 
specified timing and energy windows, a coincidence event is registered and the annihilation 
is assumed to have taken place along a line, called line-of-response (LOR), connecting the two 
detectors that registered the photons. When time-of-flight acquisition technology is used, 
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the time interval between the two arriving coincidence photons is measured, which allows 
the positioning of the annihilation event on the LOR to within a couple of centimetres. Due 
to the limited transaxial field of view (FOV), the acquisition is limited to a small (usually ≤ 25 
cm) region at a time and the whole examined area is covered by either a series of separate or 
one continuously advancing acquisition across the area of interest. During the acquisition 
millions of coincidence events called prompts are collected which can originate from either 
a true, scattered or a random event (Fig. 1). In a true coincidence event, both of the annihilation 
photons travel in a straight line to the PET detectors where they are registered. A scatter event 
is caused by one or both annihilation photons changing their trajectory and losing energy 
due to Compton scattering, while a random event is caused by two unrelated annihilation 
photons arriving to the detectors within the specified timing window erroneously causing 
a coincidence event to be registered. Both scatter and random events cause false LORs to 
be detected and need to be corrected for by algorithms calculating scatter contribution 
and estimating the number of randoms by singles count rate or a delayed timing window. 
Acquired PET data needs to be corrected for attenuation of the photons within the patient’s 
body. For this, modern PET scanners accommodate a CT part, making them hybrid PET/CT 
scanners. The CT data acquired just before or after PET scan and in the same patient position, 
can be used to assign attenuation coefficients to all voxels within the investigated volume 
to create an attenuation map and correct for loss of signal due to attenuation within the 
patient. More recently, advances in PET detectors have allowed hybrid PET/MR systems to be 
created, which provide good soft tissue contrast from the MR and lower overall radiation 
dose by skipping the CT altogether. PET/MR has however some unresolved issues due to 
lacking good attenuation correction within certain regions of the body. Additionally, the 
more complicated installation requirements and increased cost make PET/MR systems less 
popular than conventional PET/CTs.
Figure 1. Types of coincidence detection in a PET system.
True coincidence Scatter coincidence Random coincidence
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1.2.1 Corrections to raw data
The abovementioned physical and technical issues unavoidably affect the acquired data and 
cause bias and artefacts in the acquired images. In order that the final image data be suitable 
for accurate visual and quantitative evaluation, corrections need to be applied to the raw data 
before and during image reconstruction.
Attenuation correction was historically performed by irradiating the scanner FOV with a circular 
or a rotating radioactive source. These transmission measurements were used to calculate the 
attenuation coefficients within the FOV. In some cases atlas based attenuation coefficients may 
be used. All modern PET/CT systems utilise the integrated CT imaging capabilities that allow for 
a large photon flux in a short acquisition time to provide PET with an accurate attenuation 
map. For the emerging MR/PET systems, the attenuation coefficients need to be derived from 
an MR images, which requires conversion of MR data to 511kEv attenuation coefficients. The 
accuracy of MR based attenuation correction remains one of the main issues limiting the use 
in areas of the body where synthetic attenuation maps are more difficult to acquire due to no 
or minimal signal (i.e. lungs) [23–26].
Random coincidences are inevitably collected during PET acquisition and result in measured 
activity to be over-estimated unless subtracted from the initial prompts. The rate of random 
coincidences on a specific LOR is determined by the equation Ri,j =2*t*ri*rj, where Ri,j is the 
random coincidence rate between detector elements i and j, ri and rj are singles rates on 
detector elements i and j, respectively, and t is the coincidence window. So, if the ri and rj are 
measured and t known or determined, the random coincidence rate can be calculated for each 
LOR. Another way to estimate randoms rate is to use a delayed coincidence time window. In 
this way the timing signals from one of the coincidence detectors are delayed by more than the 
timing window resulting in no true coincidences to be detected therefore leaving only random 
coincidences in the prompts. The latter method has the advantage of having identical dead-
time characteristics to the prompt channel but the disadvantage of less statistics as there are 
significantly less random coincidences than singles detected.
Scatter correction became much more important as the PET technology developed and 2D 
acquisition was replaced by 3D where the lead septa separating the detector rings were 
omitted. This, coupled with the increasing transaxial range of the detectors, is contributing 
to the rapid increase of scattered coincidences detected. For the 3D acquisition mode multiple 
scatter correction methods have been proposed such as model-based algorithms, „Gaussian 
fit” technique, multiple energy window, direct measurement, Monte-Carlo modelling and 
convolution-subtraction techniques. Each of these methods provides specific advantages 
depending on the scanning geometry and the object scanned. However, there is no universally 
good method so the scatter correction methods remain active for research.
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As considers the technical limitations not all detectors exhibit identical sensitivity and 
are stable in time. Photomultiplier tubes have variations in gain which may deviate in time. 
Digital detectors are sensitive to temperature changes and may exhibit variations due to that. 
Normalisation correction is performed on the system to take into account and offset these 
differences in between the detectors. Usually, so called direct normalisation is applied, where a 
coincidence source is used to uniformly expose all detectors at once. In this way all LORs result 
in a specific number of counts, the inverse of which can then be used as the normalisation 
coefficient for that LOR in subsequent studies. Since the coefficients can change in time, the 
normalisation correction calibration needs to be performed on a regular basis. 
PET detectors have inherent limits to the rate at which new photons can be detected. 
This is due to both scintillator afterglow as well as electronics processing rate. The effect can 
be mitigated when faster electronics and scintillator materials are used. A larger number of 
discrete detectors would lessen the pile-up of signals on one detector, but the effect cannot 
be totally eliminated. Losses due to this system dead-time cause the activity in the images to 
be underestimated at high count rates which needs to be corrected for accurate quantitative 
results. This is done by modelling the dead-time losses with practical measurements and 
experiments.
In clinical practice it is essential to perform standardized uptake value (SUV) calibration. 
For this purpose a uniform phantom filled with known activity contained within an exactly 
known volume is used. Repeated usually every three months, this procedure assures a correct 
calibration between the PET image quantitative values provided as counts per second/voxel 
(cps/voxel) to the actual activity concentration (Bq/ml) within the measured object.
1.2.2 Image reconstruction
After the collection and correction of LORs, either analytical or iterative tomographic 
reconstruction methods are applied to the corrected (projection) data. While both lead to a 
final 3D dataset, the reconstruction differs a bit depending on whether the data was acquired 
in 2D or 3D mode. In 2D mode, the LORs covering single axial planes are organised into sets of 
projections covering 360°. The projections of the imaging planes placed on top of each other 
as a function of the angle of acquisition form a sinogram. Reconstruction for each of the axial 
planes is performed separately and the reconstructed slices stacked together form a final 3D 
image. In 3D acquisition mode, the LORs are available from oblique planes in addition to axial 
planes, due to the fact that the lead septa, which in 2D mode separated the planes from each 
other, were removed. This results in an increased scatter contribution as well as a larger dataset 
that is computationally more demanding.
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The reconstruction of an axial PET image from a number of projections can be performed 
either analytically, which leads to an exact solution but results in poor signal-to-noise ratio as 
well as resolution properties, or, iteratively, which however computationally more expensive, 
takes into account the stochastic nature of the data and produces more realistic system model. 
As considers the analytical 2D image reconstruction, it relies on various methods of back-
projecting the acquired projection data into the image matrix which usually includes a filtering 
step before or after the reprojection in order to counteract the inevitable oversampling in 
the centre of the Fourier transform and smooth the otherwise noisy image. In 3D analytical 
reconstruction methods, the data is initially transformed in a form that enables the use of the 
2D reconstruction methods, but with the additional statistics provided by the 3D acquisition. 
In case of iterative reconstruction methods the complexity and accuracy of the system model 
is increased and takes into account the noise introduced in the acquisition process. This results 
in a non-deterministic solution to the reconstruction problem, which cannot be solved by 
analytical means, but, by applying a step-by-step, called iterative approach to the „actual” image. 
Using iterative reconstruction methods, it is possible to achieve a more accurate estimate of 
the PET image. Iterative approaches are computationally very expensive and only recently the 
advances in computational speed and algorithms have allowed the method to be clinically used.
As described, there are multiple ways of reconstructing PET data, most of these being iterative 
in the modern PET scanners. The most widespread of the reconstruction methods is the ordered 
subset expectation maximization (OSEM) and its variations. The OSEM method inherently 
implies that a number of subsets, to which the data is subdivided to, and iteration steps, that 
are taken during reconstruction, are defined prior to the start of reconstruction. Usually, post-
filtering, using Gaussian filtering, is additionally applied to the reconstructed image.
Time-of-flight (ToF) is a method, being available due to faster scintillators and detector 
electronics, producing more accurate localisation of the annihilation event on the line-
of-response, by precisely registering the arrival times of both annihilation photons and 
calculating the location from the delay between the detection events. ToF leads to a better 
contrast vs. noise trade-off than non-TOF, especially in case of obese patients [27][28].
To improve PET spatial resolution which is degraded due to scintillator crystal size, 
penetration and scattering between neighbouring crystals as well as positron range and 
the photons’ deviation from 180° annihilation angle, during the reconstruction process a 
correction matrix is applied [29][30]. Today, all major vendors of PET/CT systems implement 
this kind of correction to the data – called point spread function (PSF), resolution recovery 
or resolution modelling. The correction significantly reduces the spill-out and spill-in effects, 
caused by incorrect activity estimates due to different activity concentrations in neighbouring 
regions, and by doing this, the contrast recovery and SUV values are increased. It is especially 
prominent in small lesions, which become more easily detectable [31][32]. 
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1.2.3 Quantitative imaging in PET
Fundamentally, PET is a quantitative imaging technique and in order to quantitatively image 
any biomarker, repeatability and reproducibility of measurements is essential. Same results 
should be achieved not only when a patient is examined repeatedly on the same scanner 
but also when the exam is performed on another system in another institution and/or from 
different vendors. 
Dynamic acquisition (with arterial blood sampling) is considered to be the „gold standard” 
in quantitative PET imaging. In this case, data is acquired during multiple time frames over 
the course of radiopharmaceutical accumulation in the area of interest providing us with 
information on tracer kinetics. This method, however, is limited due to extensive time 
required for the acquisition and interpretation. As a simpler alternative, the now widely 
used semi-quantitative metric, the standardized uptake value (SUV) has been devised. SUV 
characterizes the activity of a suspect lesion by normalizing its measured activity concentration 
to injected activity per kg of patient weight. SUV is a widely applied and simple method for 
PET quantification frequently used in [18F]FDG imaging that allows for a non-invasive tracer 
kinetics estimate from a static image. SUV, however, is affected by multiple factors (Table 1) 
– being either technical, biological or physical [33], which can introduce a bias into the data.
The most frequent technical errors are related to incorrect calibration of associated 
measurement equipment – activity meter and/or PET system – and the synchronisation of 
PET scanner and activity meter clocks. The effect of these errors can be significantly reduced 
when adequate quality control regimens are in place. The accuracy and repeatability of activity 
meter measurements should be regularly verified using appropriate check sources traceable 
back to the primary standard, while the cross-calibration of PET scanner and activity meter 
should be performed in accordance with the PET system’s manufacturer’s recommendations. 
Synchronisation of clocks may nowadays be done automatically on much of the equipment 
using Network Time Protocol (NTP) servers – this is a convenient way ensuring that the system’s 
clock is constantly checked against a known value and corrected automatically if required. 
As setting up an NTP server connection is often not possible on more simple equipment such 
as the activity meter or if patient injection is carried out manually, a regular verification of the 
associated clocks by department staff may be necessary. Operator related errors may also occur 
during every step that requires human intervention. Data entry errors (ex. injection time is 
used instead of calibration time) are a possible source of variability as long as manual data 
transfer between different systems remains regular practice. Paravenous administration of 
activity may occur if the cannula is not placed correctly and the misalignment with the vein is 
not discovered before the administration of activity. Well trained and experienced staff along 
with extra checks on critical steps of the process help reduce these kind of operator errors. 
Critical review of the images and data may retrospectively reveal some of the errors, however 
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it may not be possible to correct them thereafter, and it helps to avoid misinterpretation of 
patient data.
Patient biological factors play a major role in quantitative PET imaging. When imaging 
is done using a tracer that is naturally occurring in the body and the levels of which are 
fluctuating the effect on the uptake of the tracer can be significant. Uptake of [18F]FDG, being a 
glucose analogue, is significantly affected by the natural blood glucose levels during the FDG 
uptake period. If high glucose levels are present during this uptake period, the additionally 
injected FDG will have to compete with glucose and therefore a smaller amount is 
accumulated in the tissues, in comparison with a lower glucose level. Glucose measurement 
prior to administering FDG is a good way to check if the blood glucose levels are not too high. 
Using a calibrated glucometer, it is possible to take the measured value into account when 
calculating a glucose corrected SUV. Regardless of radiotracer, if no arterial blood sampling 
is used, it is difficult to estimate the amount of activity leaving the blood pool and taken up 
in the organs, which may vary in time and from patient to patient. As a solution the ratio of 
SUV from two different regions (target and reference) within the same image/study may be 
calculated, resulting in a SUVR metric. Variations in uptake time of the radiotracer are having 
impact on quantitative results. For instance, in FDG imaging SUV is known to increase when 
the time interval between injection and imaging increases. This effect can be offset when 
a specific uptake time, standard to the imaging procedure is applied. There are additional 
patient related factors that cannot be totally eliminated such as patient motion during the 
acquisition – whether due to breathing, peristaltics or comfort during a lengthy procedure or 
inflammation caused by possibly unrelated and unpredictable conditions.
Acquisition and reconstruction parameters play a major role in achieving accurate and 
repeatable quantification in PET. Scan duration along with reconstruction parameters such 
as image matrix size and post filtering directly affects the amount of noise present in the final 
images. This may in turn affect the quantitative results achieved using some SUV metrics. 
An upward bias results from using SUVmax on images with higher noise. Reconstruction 
parameters such as number of iterations and subsets along with post filter values may 
differ in scanners due to technical limitations, preferences of the reporting physicians and 
imaging task. This leads to variability in the quantitative results that is dependent on the 
activity concentration and size of the object imaged as well as the activity in surrounding 
tissues. Recently developed corrections, such as resolution recovery, present on modern 
PET/CT systems can significantly increase the SUV of smaller lesions but have a distinct noise 
texture [31][34] and produce edge overshoot and focal uptake hyper-resolution artefacts 
[35][36]. Quantification depends on the definition of the measured volume - or volume of 
interest (VOI) to be measured. In practice a tumour is usually delineated using automatic 
region drawing methods with cut-off values based on either user defined (i.e. SUV ≥ 4.0) 
or object determined (SUVmax) values. These methods may further vary due to different 
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implementation by vendors which may include, exclude or use interpolation of voxel values 
for lesion border definition. As there are many factors affecting the reconstruction and 
measurement, which cannot be precisely characterised beforehand, it is useful to practice 
harmonisation of the resulting recovery coefficients.
Factor Mitigation
Technical errors
Activity meter calibration error Regular quality checks and traceable calibration
Cross-calibration of activity meter 
and PET
PET is regularly calibrated using same activity meter, 
harmonisation programs
Incorrect synchronisation of clocks 
on PET system and activity meter
Regular checks by staff or automated synchronisation 
if possible
Residual activity after administration Residual activity is measured and taken into account
Data entry errors Use of automated transfer of data
Paravenous administration of activity Test bolus injection, retrospective image analysis
Biologic factors
Blood glucose level Specific fasting and measurement of blood glucose before 
the study
FDG clearance from blood Normalise SUV to blood uptake (SUVr)
Uptake period Standardised uptake period
Patient motion Comfortable position, gating systems, correction algorithms
Inflammation Pre-scan patient questionnaires
Physical factors
Acquisition parameters Noise reduction algorithms, adapt protocol for 
Reconstruction parameters Harmonisation programs
Region of interest (ROI) used Automated standardised tools for repeatable lesion delineation
SUV type used Clear specification of used metrics
Blood glucose level correction Proper fasting procedures
Use of contrast agents during CT-AC Scanning in venous phase, specific CT corrections
Table 1. Factors affecting [18F]FDG PET quantification.
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1.3 Multicentre standardisation programs
Due to the wide spread of PET/CT systems, the number of multicentre trials (such as ABLE, 
RAPID, FALCON and many others) involving them has increased throughout recent years, and 
quantitative evaluation and endpoints are more frequently used [37][38]. In order to achieve 
best multicentre standardisation and harmonisation, the sources of variability should be 
considered and their effects minimised as much as possible. Rapid advancement and different 
levels of technology in various imaging centres pose a particular problem to standardisation 
as the benefits offered by modern technologies, such as PSF or ToF, provide increased benefit 
over the older technologies. This creates difficulties in comparing the data acquired on 
different generation systems. There is a number of guidelines and standardisation programs 
developed by professional and scientific societies and organisations which aim at reducing 
this variability by standardising the involved procedures and/or harmonising the PET/CT 
system performances [39–43].
Society of Nuclear Medicine and Molecular Imaging (SNMMI) has been running the Clinical 
Trials Network (CTN) since 2008 to ensure baseline common quality control metrics for 
participating PET scanners used in multi-centre studies. Scanner validation requires the use 
of program specific CTN phantom – an anthropomorphic phantom mimicking a human torso 
to provide qualitative and quantitative information in conditions similar to clinical imaging 
settings. An acceptance criteria of ±10% is set for the background region SUVmean, but 
precise sphere-specific acceptance criteria for SUVmax and SUVmean for the various sphere 
sizes are currently not strictly set [44]. Scanner re-validation, including phantom scanning, 
is repeated annually.
From 2003, the American College of Radiology Imaging Network (ACRIN) PET Core 
Laboratory qualifies sites for participation in multicentre trials. To do this, each site is required 
to submit data from one uniform cylinder scan and two patient test cases. The uniform 
cylinder scan is analysed in the core lab by calculating the mean SUV of each transverse slice, 
while in order to pass, the average SUV is required to be within 1.0 ± 0.1. Patient scans are 
qualitatively evaluated for artefacts, noise, patient positioning and PET - CT image alignment. 
In addition, the core lab calculates SUVs from the ROIs comprising the livers of submitted 
patients’ scans and compares them with the reported data. This is aimed at evaluating the 
level of expertise of PET/CT camera operators. No acceptance criteria for size specific contrast 
recovery coefficients is set [45].
Radiological Society of North America - Quantitative Imaging Biomarkers Alliance (RSNA-
QIBA) provides guidelines and instructions on how to measure SUV calibration as well 
as uniformity between slices of a uniform cylindrical phantom. „Acceptable” and „ideal” 
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performance measurement methods and criteria are described for uniformity, resolution/SUV 
recovery and noise. Criteria of ACRIN/EANM/SNM are frequently referred to. The results of the 
quality control measurements are to be submitted annually and should be available for any 
site audit [46].
National Cancer Research Institute (NCRI) PET Clinical Trials Network provides more a specific 
accreditation on a per trial basis, where the Core Lab reviews the trial protocol in the setup 
phase and determines specific requirements for the participating system’s quality assurance. 
This results in a uniform distribution of scanners within a single trial, but, requires multiple 
levels of standardisation which creates difficulties in intercomparison. 
The European Association of Nuclear Medicine (EANM) published the guideline „FDG PET and 
PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0” in 2010 [47] which was 
followed by and updated version 2.0 in 2014 [48]. As a support for the clinical application of the 
EANM guideline, the EANM-EARL initiative provides an accreditation service based on regular 
independent review of phantom scans which are required to be performed by the imaging 
sites participating in the program. Quarterly, a uniform cylinder needs to be scanned and data 
submitted to be evaluated centrally for SUV calibration check in order to ensure that the mean 
SUV is within the acceptance range of 1.0 ± 0.1. Annually, the NEMA body phantom should 
be scanned for the evaluation of image quality and contrast recovery of the six hot spheres 
of varying diameters (10 – 37 mm). In order that the imaging sites maintain their accredited 
status, the contrast recoveries mean and max SUVs needs to comply with the accreditation 
specifications. In addition to periodically providing phantom scans, the accredited sites have 
to apply the EANM procedure guidelines [48]. 
EANM EARL aims at constantly adapting, improving and expanding based on recent scientific 
discoveries, technical developments of the equipment and requirements of the nuclear 
medicine community. Work described in this thesis focuses on the EANM guidelines and 
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1.4 Thesis aim
EANM-EARL [18F]FDG PET/CT accreditation programme has been running successfully from 
2010, applying the standard criteria developed by EARL for the scanners used in clinical 
practices. As new technology appears on the market and advances are being made in using 
novel tracers, the existing quantitative imaging standardisation programs need to be adapted 
and evolve along with the field, in order to remain relevant in the constantly changing 
environment.
This thesis aims at investigating the current status and results of the EANM-EARL [18F]FDG 
PET/CT accreditation programme and explore the feasibility of an update on the current 
harmonising standards. 
Another goal of this work is to expand the EANM-EARL accreditation program to include 
additional radioisotopes and tracers besides [18F]FDG.
1.5 Thesis outline
Chapter 2 describes six years’ experience of running the EANM-EARL [18F]FDG PET/CT 
accreditation programme and reports the findings and impact on the participating nuclear 
medicine centres. In Chapter 3 the feasibility of harmonising state-of-the-art PET/CT 
systems equipped with time-of-flight (ToF) and resolution modelling capabilities is explored. 
Additionally, a prototype of updated harmonising criteria is developed and suggested for 
application by EARL. Chapter 4 investigates the impact of updated EARL harmonising criteria 
on quantitative reads of clinical PET/CT studies and tests a method of bridging the old and 
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2.1 Abstract
Purpose: From 2010 until July 2016 EANM Research Ltd. (EARL) FDG-PET/CT accreditation 
program has collected over 2500 phantom datasets from approximately 200 systems and 150 
imaging sites worldwide. The objective of this study is to report the findings and impact of the 
accreditation program on the participating PET/CT systems.
Methods: To obtain and maintain EARL accredited status, sites were required to complete 
and submit two phantom scans - calibration quality control (CalQC), using a uniform cylindrical 
phantom and image quality control (IQQC), using a NEMA NU2-2007 body phantom. Average 
volumetric SUV bias and SUV recovery coefficients (RC) were calculated and the data evaluated 
on the basis of quality control (QC) type, approval status, PET/CT system manufacturer and 
submission order. 
Results: SUV bias in 5% (n=96) of all CalQC submissions (n=1816) exceeded 10%. After 
corrective actions following EARL feedback, sites achieved 100% compliance within EARL 
specifications. 30% (n=1381) of SUVmean and 23% (n=1095) of SUVmax sphere recoveries 
from IQQC submissions failed to meet EARL accreditation criteria while after accreditation, 
failure rate decreased to 12% (n=360) and 9% (n=254) respectively. Most systems demonstrated 
longitudinal SUV bias reproducibility within ±5%, while RC values remained stable and 
generally within ±10% for the four largest and ±20% for the two smallest spheres.
Conclusions: Regardless of manufacturer or model, all investigated systems are able to 
comply with the EARL specifications. Within the EARL accreditation program gross PET/CT 
calibration errors are successfully identified and longitudinal variability in PET/CT performances 
reduced. The program demonstrates that a harmonising accreditation procedure is feasible 
and achievable.
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Positron emission tomography (PET) and computed tomography (CT) hybrid imaging 
(PET/CT) using 18F-fluorodeoxyglucose (FDG) has become a routinely used and valuable tool 
in oncology. It is widely utilised for diagnosis, staging and restaging of various malignancies 
[1–12] as well as response monitoring due to its ability to measure metabolic changes [13–
19]. Standard uptake value (SUV), which represents the tissue radioactivity concentration 
normalized to injected activity and body weight [20] is the most frequently used quantitative 
metric in oncology [21,22]. Multiple factors, however, can give rise to bias [23–25] and increased 
variability in SUV, especially when inter-centre comparison is required from institutions 
lacking a uniform approach to imaging procedures [26–28]. The variability is a significant issue 
for clinical trials or multicentre studies utilising the quantitative potential of PET [24,26–31]. 
In clinical practice, there is a wide range of PET systems installed globally including scanners 
developed more than 10 years ago along with brand new devices incorporating state of the 
art acquisition (i.e. time of flight, digital PET detectors) and reconstruction (i.e. resolution 
modelling) technologies [32]. In addition to various PET/CT models available, the acquisition 
and reconstruction parameters applied at different sites vary greatly due to local preferences 
[24,32,33]. Centres equipped with PET systems having new acquisition and reconstruction 
technologies available, often tend to aim for the possible best lesion detection which may 
not be in line with quantitative harmonising standards [34]. Aforementioned technical factors 
impose a significant source of variability in PET quantification [24,32] that should be addressed 
by the international community.
Numerous professional societies and organizations such as the Society of Nuclear Medicine 
and Molecular Imaging (SNMMI), American College of Radiology Imaging Network (ACRIN), 
Radiological Society of North America - Quantitative Imaging Biomarkers Alliance (RSNA-
QIBA), The American Association of Physicists in Medicine (AAPM) and the European 
Association of Nuclear Medicine (EANM) are promoting harmonisation of imaging procedures 
[35–37] in order to reduce the variability of PET image quantification in a multicentre setting. 
Many of these programs rely on quality control procedures utilising standard phantoms [38] 
for standardization of quantification [32,39–41] and harmonisation of PET/CT systems [35]. 
Review papers on describing some of the results and experience in running such programs 
have been published by Scheuermann et al. [39] and more recently by Sunderland et al. [32].
In 2006, the European Association of Nuclear Medicine (EANM) launched the EANM Research 
Ltd (EARL) initiative. One of the main objectives of the program has been promoting multicentre 
nuclear medicine and research. In 2010, the FDG-PET/CT accreditation program was created 
in order to address variability in the quickly growing field of quantitative FDG-PET imaging 
by setting up guidelines and specifications to which the participating sites must adhere to. 
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The specification bandwidths for the current EARL specifications were developed during a pilot 
study in 2010-2011 involving 12 PET/CT systems. Based on this study, specifications for SUVmean 
and SUVmax recovery coefficients were derived which accommodated all investigated systems. 
From its initiation until July 2016, EARL has collected approximately 2500 phantom datasets from 
more than 200 PET/CT systems from over 150 imaging sites worldwide. The data analysed by EARL 
encompasses majority of the system types in clinical use over the past 10 years and incorporates 
sites with various backgrounds giving it a broad basis to represent the field as a whole.
The objective of this paper is to report the findings obtained so far in the EARL standardisation 
program and their impact on the quantitative variability of accredited PET/CT systems. Analysis 
of phantom scans from the largest number of active PET centres so far provides representative 
details of current quantitative capabilities of FDG-PET imaging and the variability to be 
expected. Understanding the characteristics of variability and the impact on standardization 
will help planning multi-centre clinical trials, utilising quantitative FDG-PET/CT imaging and 
advance use of PET as a quantitative imaging biomarker.
The secondary objective of this study is to explore ways to improve the EARL FDG-PET 
accreditation program based on the retrospective analysis of phantom data collected in the 
EARL database.
2.3 Materials and methods
2.3.1 Acquisition and submission of data to EARL
Sites, which are seeking EARL FDG-PET/CT accreditation for the first time, need to pass the 
initial procedure. This procedure includes the submission of an online questionnaire and a 
signed statement – these documents have to be submitted at the start of the accreditation 
procedure and revised annually, whereas QC documents need to be regularly provided in order 
to maintain the EARL accredited status. 
For the first and follow up procedures, sites have to perform calibration QC and image quality 
QC measurements. The calibration QC measurements have to be repeated every 3 months 
and image quality QC procedures annually, while the data needs to be provided to EARL upon 
completion of the procedures. During each round of QC survey there is a 3 week period for the 
sites to collect the data and submit it to EARL, followed by a 3 week period of analysing the data 
by EARL and reporting the results back to the sites.
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For the calibration QC measurements, centres are asked to use a cylindrical phantom with 
the following characteristics: diameter of about 20 cm (17 to 22 cm) and length sufficient to 
cover the entire axial field of view (FOV). Furthermore, the exact volume of the calibration 
phantom should be known and recorded in the calibration QC scan report form. The phantom 
has to be filled with water and about 70 MBq 18F-FDG added to it, aimed at expected phantom 
acquisition time. 
For image quality QC measurements, the NEMA NU2-2007 image quality phantom is required. 
The phantom has a fillable torso cavity to act as a background compartment, a 5 cm diameter 
cylindrical lung insert in the centre and 6 fillable spheres with internal diameters of 10 mm, 
13 mm, 17 mm, 22 mm, 28 mm and 37 mm positioned coaxially around the lung insert. The 
phantom background compartment and the spherical inserts have to be filled with 18F-FDG 
solution aimed at activity concentrations at the start of the PET scan of 2 kBq/mL and 20 kBq/mL, 
respectively, resulting in a sphere to background ratio of 10:1.
With both phantoms, routine quantitative whole body PET/CT scans have to be performed 
with 2 PET bed positions of at least 5 min each, including a (low dose) CT for attenuation 
correction purposes [35]. After reconstruction, the attenuation corrected PET, non-attenuation 
corrected PET and CT images of the phantoms have to be uploaded into the EARL central 
database, along with scan report forms. 
2.3.2 Quantitative analysis and approval by EARL
The uniform calibration QC phantom and NEMA NU2 IQ body phantom images uploaded 
into the EARL database are evaluated centrally, making use of a standardized semi-automatic 
quantitative analysis tool developed internally within EARL. The software uses activity and time 
information provided by the scan report forms. The average volumetric SUV bias is generated as 
relative deviation between measured and calculated activity concentration values (equation 1). 
The SUV recovery coefficients (RCs) for the 6 spherical inserts are based on 50% background 
corrected isocontour VOI (RCSUVmean) and maximum voxel value included in the VOI (RCSUVmax).




Cmeasured - activity concentration measured from images
Ccalculated - activity concentration calculated from injection data
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EARL is applying SUV bias and RC values acceptance criteria, which were defined by feasibility 
studies performed on the systems used in clinical practices at the start of the standardisation 
- a study is underway in order to update these. When approval is not granted, the site 
undergoing (re-)accreditation is asked to take corrective actions, for example: recalibration 
of the PET system, adjustment of reconstruction parameters, repeating the phantom scan 
and so on. When required, EARL is advising the sites. A Manual describing the accreditation 
program in detail as well as information on the EARL website [42] is also available. If submitted 
QC documents meet the standard requirements, FDG-PET/CT accreditation is granted and the 
department is listed on the EARL website (http://earl.eanm.org) as an accredited PET/CT centre 
of excellence. Furthermore, the site is provided with an accreditation certificate and signet, 
which can be used on its correspondence and website. 
2.3.3 Data clean-up and preparation
To allow for data extraction, the EARL database had to be cleaned of duplicates and entries 
with insufficient or missing information removed, entry errors were identified and the 
individual site identification data ignored thereby providing an anonymised set of data for 
evaluation. First and subsequent site submissions were identified and marked as such.
2.3.4 Analysis 
The calibration QC and image quality QC datasets from the EARL database will be analysed 
based on the type of the phantom, accreditation approval status, manufacturer of the PET/
CT system and whether it was the first or a subsequent QC data submission. The SUV bias and 
normalised SUV biases were analysed as well as the recovery coefficients for each sphere size, 
separately for SUVmean and SUVmax. For each parameter, mean, median, standard deviation, 
standard error and skewness were calculated. Longitudinal reproducibility analysis was 
performed on 16 systems (systems A to P) selected based on each having sufficient longitudinal 
data of at least 18 approved CalQC data submissions or at least 5 approved IQQC datasets. 
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Data reviewed in this paper encompasses all submissions to the EARL database from the 
initiation of the standardisation program in November 2010 to July 2016. Figure 1 represents 
the number of sites and systems participating each year. After correcting for erroneous, 
partial and duplicate entries, 1816 CalQC and 778 IQQC datasets were used for further analysis. 
The datasets were 29% (n=752) from GE-, 29% (n=741) from Philips- and 42% (n=1101) from 
Siemens-systems.
First data submissions constitute 10% (n=175) of all CalQC and 23% (n=178) of all IQQC scans. 
85% (n=149) of the first and 94% (n=1537) of subsequent CalQC data submissions could be 
approved by EARL. This results in an overall approval rate for CalQC of 93% (n=1686). Table 1 
states descriptive statistics for CalQC initial and subsequent submissions.
Out of all systems (n=200) that have enrolled in the program, the accreditation for 47 systems 
(24%) has been discontinued for various reasons, such as scanner replacement or stopped 
participation in trials requiring EARL accreditation.
2.4.2 Calibration QC
Detailed descriptive statistics for CalQC SUV bias are summarised in Table 1. Figure 2 
demonstrates CalQC SUV bias distribution for all, initial and subsequent submissions along 
with vendor based distribution of approved results. 3% (n=60) of all CalQC submissions 
were below and 2% (n=36) above the corresponding EARL SUV bias limits of -10% and +10%. 
9% (n=16) of systems could not be approved at first CalQC submission, but after corrective 
actions all of the scanners fulfilled the EARL specifications. Significant mean SUV biases of 
-1.53% (p<0.0001) and -1.78% (p<0.0001) were observed in approved datasets from GE and 
Philips systems respectively, while datasets from Siemens systems did not demonstrate this 
deviation. In figure 3 longitudinal CalQC volumetric SUV bias is plotted as a function of the 
order of subsequent submissions. 
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Fig 1. Number of sites and PET/CT systems participating in the EARL accreditation program. 
For 2016 data has been collected from January to July.
CalQC
Mean SUV bias 
(%)
Median 


















All CalQC -1.14 (±0.13) -1.01 5.36 -0.32 3% 2% 95%
All approved CalQC -0.97 (±0.09) -0.94 3.71 0.15 0% 0% 100%
Sites’ first submitted 
CalQC
-1.25 ±0.46) -0.79 6.06 -1.14 6% 3% 91%
Subsequent approved 
submissions CalQC
-1.01 (±0.09) -1.02 3.66 0.16 0% 0% 100%
All approved GE 
CalQC
-1.53 (±0.15) -1.60 3.27 0.31 0% 0% 100%
All approved Philips 
CalQC
-1.78 (±0.18) -1.71 3.89 0.26 0% 0% 100%
All approved Siemens 
CalQC
-0.05 (±0.14) 0.06 3.65 0.01 0% 0% 100%
Table 1. CalQC SUV bias statistics from first, regular ongoing and all EARL approved submissions 
(pooled and per vendor).
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Fig 2. Comparison of CalQC SUV bias distribution for all, initial and subsequent submissions along 
with vendor based distribution of approved results. The dotted horizontal lines represent EARL 
specification limits. Central line of the box is the median, edges of the box are the 25th and 75th 
percentiles, the whiskers extend to either the most extreme data points which are not considered 
outliers or 1.5 times interquartile range. The outliers are marked using plus signs.
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Fig 3. Longitudinal plots of EARL approved CalQC results from the 16 systems. SUV bias deviation 
from the expected value. The dotted horizontal lines represent EARL specification limits. Central 
line of the box is the median, edges of the box are the 25th and 75th percentiles, the whiskers 
extend to either the most extreme data points which are not considered outliers or 1.5 times 
interquartile range. The outliers are marked using plus signs.
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2.4.3 Image Quality QC
Descriptive statistics for IQQC SUVmax and IQQC SUVmean results for each sphere size are 
summarised in supplemental tables 1 and 2. Supplemental figure 4 shows the distribution 
of sphere recoveries of all submitted data and approved IQQC submissions along with SUV 
recovery distributions separately per manufacturer. A large variability in sphere recoveries was 
observed. Out of all sphere recoveries from IQQC datasets, 30% (n=1381) of SUVmean and 23% 
(n=1095) of SUVmax recoveries failed to meet the EARL accreditation criteria. After corrective 
actions the corresponding values dropped to 12% (n=360) and 9% (n=254) respectively. 
A positive bias in the recovery values was observed prior to and also after the corrective actions 
and granted accreditation, respectively. 47% (n=84) of sites’ initial IQQC submissions and 68% 
(n=409) of all consecutive IQQC submissions were approved by EARL. Overall approval rate for 
IQQC submissions was 63% (n=493).
To evaluate the longitudinal performance of the 16 systems, sphere recoveries for all sphere 
sizes were plotted based on the order of subsequent submissions, as seen in supplemental 
figure 5. From the figure, it can be seen that for each sphere there is an initial large variability 
in observed SUV recoveries which is reduced and becomes harmonized during subsequent 
submissions.
2.5 Discussion
The number of sites participating in the EARL accreditation program is steadily increasing 
and the received data is almost equally distributed among the three major PET/CT system 
manufacturers.
Inconsistency was observed in the names provided for same types of systems and in some 
cases the device serial numbers were missing or had been changed at the occasion of software 
upgrade or service maintenance. This complicated the distinction between new systems and 
those already existing in the EARL database. As a solution, the EARL database client portal could 
be configured so that the system type selection be performed by choosing from a predefined 
list, in the same way as it currently works for system manufacturer, permitting that the regularly 
submitted QC data be checked and if necessary, corrected for constancy of the core data and the 
device serial number in particular. 
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A small number (n=19) of calibration QC submissions were not included in further analysis 
due to large SUV biases observed. The high values might have been related to improper data 
communication from the participants, inhomogeneous phantoms or system failures left 
unnoticed by the centres. In all these cases, sites were asked to implement corrective actions 
and redo the experiments. As a result, all of the affected systems achieved compliance with the 
EARL specifications and were granted accreditation.
Regardless of manufacturer or model, all systems were able to comply with the CalQC 
specifications set up by EARL. Only 9% of sites first QC submissions and 5% of all CalQC 
submissions demonstrated a measured activity bias of more than 10%. Scheuermann et al. in 
their review of ACRIN PET Core Laboratory program reported a similar initial SUV or normalization 
calibration failure rate of 12% within the same acceptance criteria of SUV 1.0 ± 0.1 [39].
Compared to all received data, the non-compliances were almost eliminated in EARL approved 
data. In the datasets reviewed and approved by EARL, all CalQC SUV biases fall within the range of 
±10.5%, which aligns with the target of ±10%. Although the fraction of non-approved data from 
combined first and regular submissions was relatively small (about 5%), the importance of this 
fact should not be underestimated since noncompliance in calibration QC procedure means 
gross error in basic system calibration which would affect all further PET quantitative evaluations.
CalQC average values demonstrate a slight but statistically significant underestimation of 
the activity concentration or SUV by Philips and GE systems, while data from Siemens devices 
do not show this deviation. Scheuermann et al. reported similar results for Philips systems 
[39]. Whether this is due to some systematic differences among the vendors’ calibration 
procedures, drifts in calibration values or some unknown effects, could not be derived from 
the current data but should be subject for further investigations. However, it is important to 
note that these errors were well within 2% and are very likely to be clinically irrelevant.
Longitudinal analysis of the CalQC results from 16 selected systems, visualised in supplemental 
figure 6, illustrates good performance of the systems and reflects the quantification stability 
achieved by the accredited sites. Large SUV biases were only occasionally observed, and were 
all corrected by the sites after receiving notification from EARL. In most of the cases corrective 
action had been taken within 4 weeks.  
The majority of PET/CT systems followed throughout the investigation period showed good 
reproducibility of the CalQC results seen in figure 3. Longitudinal SUV bias values lie mostly 
within ±5% of the expected value, which is in agreement with data published by Geworski et 
al. [43] and more recently by Sunderland et al. [32]. The rest of the systems also meet the ±10% 
calibration accuracy criteria. Our findings suggest opportunities for the implementation of 
stricter accreditation specification for EARL CalQC SUV biases.
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The comparison between all received and EARL approved data indicates significant 
reduction of outliers for IQQC results (supplemental tables 1 and 2). However, some of 
the data not strictly within EARL specifications was still accepted after critical review. This 
means the noncompliant data was deemed acceptable in case only one of the spheres being 
slightly out of the specifications, but the overall shape and magnitude of RC curve could 
be determined to a sufficient extent and being compliant with EARL criteria. Moreover, 
in these cases submissions were reviewed retrospectively and consistency of acquisition, 
reconstruction and settings was verified. While in case of the larger diameter spheres 
meeting EARL specifications was common, for the smallest sphere (10 mm diameter) 
SUVmax data remained outside of specified bandwidth in 26% of the EARL approved 
submissions. Achieving harmonised quantitative results for the smallest sphere turned out 
to be challenging due to its increased sensitivity to image noise and phantom positioning 
within the PET field of view. 
Although in most cases when the spheres’ RCs did not meet the specifications, sites were 
asked to redo experiments, still a noticeable upward bias in results for the smallest sphere 
could be observed. Therefore, based on these findings EARL implemented slightly adjusted 
recovery specifications for the smallest sphere starting from the 1st of January 2017.
Prior to harmonisation, the average recoveries of all spheres demonstrated a positive bias 
compared to EARL specifications. The trend could still be observed to some extent within the 
approved results. This can be attributed to both the vendors and sites preferences leaning 
towards reconstruction algorithms emphasizing contrast and detectability. The positive bias in 
the case of 10 mm diameter sphere might also be attributed to newly adopted acquisition and 
reconstruction technologies (e.g. including resolution modelling), which aims at increasing 
small lesion detectability. This trend was also observed by Sunderland at al. who showed that 
recoveries were generally higher for systems employing TOF and PSF reconstructions [32]. 
Since more modern PET/CT systems with new technologies appear in the field, a review of 
the existing EARL specifications is required in order to facilitate the inclusion of the increased 
contrast recovery capabilities of these systems. EARL is currently carrying out a feasibility 
study aiming at redefining the accreditation criteria by taking into account not only the new 
technologies but also considering that the majority of the PET/CT systems currently in clinical 
use should be able to comply. 
By comparing the first and following regular submissions from participating sites, a relative 
increase can be observed in meeting the EARL specifications which is expected since the 
accredited sites gain experience in performing quantitative calibrations and assessment of 
their systems. The staff’s increased awareness towards the necessity of regular calibration 
and quality control of the systems is one of the benefits of participation in an accreditation/
standardisation program, which is difficult to measure but should not be underestimated. 
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IQQC longitudinal analysis results, presented in figure 5, visualize the major improvement 
of regular submissions in relation to the first submission. As the sphere size decreases, the 
improvement becomes more prominent. After initial adjustment of the reconstruction parameters, 
the longitudinal reproducibility remains stable and generally within ±10% for the largest 4 
spheres and ±20% for the smallest 2 spheres. These findings emphasise that PET/CT performance 
and the execution of the QC experiments show high reproducibility and demonstrate that long 
term maintenance of a harmonised PET/CT network is feasible and achievable. 
2.6 Conclusion
The European Association of Nuclear Medicine (EANM) has been running an FDG-PET/CT 
accreditation program under the EANM Research Ltd (EARL) initiative in order to harmonise 
quantitative PET/CT performance and facilitate multi-centre nuclear medicine and research. 
The number of sites and systems participating in the accreditation program has steadily 
increased over the years with similar numbers of scanners from each of the 3 major vendors.
Outliers observed in the overall submissions of both CalQC and IQQC were largely eliminated 
in subsequent submissions after notification from EARL. Excellent longitudinal performance 
was observed in most of the systems – majority demonstrated CalQC values reproducible 
within 5% and IQQC results within 10% for the largest 4 spheres and 20% for the smallest two 
spheres. Occasional deviations from expected values were rapidly resolved by the sites after 
notification from EARL. Regardless of system manufacturer or model, all vendors were able to 
comply with the accreditation specifications set out by EARL. 
Prior to harmonisation, IQQC data demonstrated a slight positive bias relative to EARL 
specifications, which suggested to carry out a review and update in order to account for the 
advances in acquisition and reconstruction technologies in PET/CT.
In this manuscript we have demonstrated that the EARL accreditation program can 
successfully identify gross PET/CT calibration errors and reduces variability in PET/CT 
performance by longitudinally performing harmonisation QC experiments. The program 
is running successfully for more than 6 years and shows that a harmonising accreditation 
procedure is feasible and achievable. 
Centres with accredited PET/CT systems benefit greatly from participating in large-scale 
accreditation programs which facilitate the implementation of procedural guidelines widely 
recognised by the imaging community.
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All 37mm sphere 
SUVmax
1.08 (±0.01) 1.06 0.156 12.9 6% 13% 81%
Approved 37mm 
sphere SUVmax
1.05 (±0.01) 1.04 0.160 18.5 2% 2% 96%
All 28mm sphere 
SUVmax
1.05 (±0.01) 1.03 0.150 12.7 4% 13% 83%
Approved 28mm 
sphere SUVmax
1.03 (±0.01) 1.02 0.154 18.9 0% 2% 98%
All 22mm sphere 
SUVmax
1.02 (±0.01) 1.01 0.144 10.2 1% 17% 83%
Approved 22mm 
sphere SUVmax
1.00 (±0.01) 0.99 0.140 17.9 0% 3% 97%
All 17mm sphere 
SUVmax
0.95 (±0.01) 0.93 0.152 6.9 2% 23% 75%
Approved 17mm 
sphere SUVmax
0.92 (±0.01) 0.91 0.138 14.1 1% 8% 92%
All 13mm sphere 
SUVmax
0.73 (±0.01) 0.71 0.168 3.6 11% 14% 75%
Approved 13mm 
sphere SUVmax
0.70 (±0.01) 0.69 0.123 11.9 6% 2% 92%
All 10mm sphere 
SUVmax
0.47 (±0.01) 0.45 0.139 3.2 6% 32% 62%
Approved 10mm 
sphere SUVmax
0.45 (±0.01) 0.44 0.108 8.8 3% 23% 74%
2.8 Supplementary material
Supplemental table 1. IQQC SUVmax statistics for all sphere sizes calculated for all received and 
EARL approved submissions.
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All 37mm sphere 
SUVmean
0.85 (±0.01) 0.84 0.112 15.0 7% 18% 76%
Approved 37mm 
sphere SUVmean
0.83 (±0.01) 0.83 0.120 19.4 2% 4% 94%
All 28mm sphere 
SUVmean
0.80 (±0.01) 0.79 0.111 13.9 7% 17% 76%
Approved 28mm 
sphere SUVmean
0.79 (±0.01) 0.79 0.116 19.6 2% 3% 95%
All 22mm sphere 
SUVmean
0.76 (±0.01) 0.75 0.107 11.3 1% 32% 67%
Approved 22mm 
sphere SUVmean
0.75 (±0.01) 0.74 0.106 18.7 0% 14% 86%
All 17mm sphere 
SUVmean
0.69 (±0.01) 0.68 0.111 7.0 4% 25% 71%
Approved 17mm 
sphere SUVmean
0.67 (±0.01) 0.67 0.101 14.4 1% 9% 89%
All 13mm sphere 
SUVmean
0.54 (±0.01) 0.52 0.118 4.0 10% 17% 73%
Approved 13mm 
sphere SUVmean
0.52 (±0.01) 0.52 0.088 12.9 5% 4% 90%
All 10mm sphere 
SUVmean
0.36 (±0.01) 0.35 0.105 2.5 10% 30% 60%
Approved 10mm 
sphere SUVmean
0.34 (±0.01) 0.34 0.082 7.2 7% 21% 73%
Supplemental table 2. IQQC SUVmean statistics for all sphere sizes calculated for all received and 
EARL approved submissions.
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Supplemental Fig. 4. IQQC SUVmean (a to f) and SUVmax (g to l) recovery results, regular 
ongoing and all EARL approved submissions (pooled and per vendor). Dots represent EARL 
specification limits. Central line of the box is the median, edges of the box are the 25th and 75th 
percentiles, the whiskers extend to either the most extreme data points which are not considered 
outliers or 1.5 times interquartile range. The outliers are marked using plus signs.
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Supplemental Fig. 5. Longitudinal analysis of IQQC results from 16 scanners. Recovery coefficients 
biases from the mean of the respective scanner. „Initial” data series represents the first IQQC 
submission for each system. Central line of the box is the median, edges of the box are the 25th 
and 75th percentiles, the whiskers extend to either the most extreme data points which are not 
considered outliers or 1.5 times interquartile range. The outliers are marked using plus signs.
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Supplemental Fig. 6. Longitudinal analysis of the 16 systems’ CalQC results. SUV bias values 
for each system are presented as separate lines. Dotted lines represent outliers and dashed lines 
subsequent corrective actions. Red dots represent datapoints outside EARL specifications.
541106-L-bw-Kaalep




1. Fletcher JW, Djulbegovic B, Soares HP, Siegel B a, 
Lowe VJ, Lyman GH, et al. Recommendations on 
the use of 18F-FDG PET in oncology. J. Nucl. 
Med. 2008;49:480–508. 
2. de Geus-Oei L-F, van der Heijden HFM, Corstens 
FHM, Oyen WJG. Predictive and prognostic 
value of FDG-PET in nonsmall-cell lung cancer: 
a systematic review. Cancer. 2007;110:1654–64. 
3. Shankar LK, Hoffman JM, Bacharach S, 
Graham MM, Karp J, Lammertsma AA, et al. 
Consensus Recommendations for the Use of 
18F-FDG PET as an Indicator of Therapeutic 
Response in Patients in National Cancer Institute 
Trials. J Nucl Med. 2006;47:1059–66. 
4. Gupta T, Master Z, Kannan S, Agarwal JP, 
Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic 
performance of post-treatment FDG PET or 
FDG PET/CT imaging in head and neck cancer: a 
systematic review and meta-analysis. Eur. J. Nucl. 
Med. Mol. Imaging. 2011;38:2083. 
5. Ung YC, Maziak DE, Vanderveen JA, 
Smith CA, Gulenchyn K, Lacchetti C, et al. 
18Fluorodeoxyglucose positron emission 
tomography in the diagnosis and staging of lung 
cancer: A systematic review. J. Natl. Cancer Inst. 
2007;99:1753–67. 
6. Lv Y-L, Yuan D-M, Wang K, Miao X-H, Qian Q, 
Wei S-Z, et al. Diagnostic performance of 
integrated positron emission tomography/
computed tomography for mediastinal lymph 
node staging in non-small cell lung cancer: a 
bivariate systematic review and meta-analysis. J. 
Thorac. Oncol. International Association for the 
Study of Lung Cancer; 2011;6:1350–8. 
7. Eschmann SM, Friedel G, Paulsen F, Reimold M, 
Hehr T, Budach W, et al. 18F-FDG PET for 
assessment of therapy response and preoperative 
re-evaluation after neoadjuvant radio-chemotherapy 
in stage III non-small cell lung cancer. Eur. J. Nucl. 
Med. Mol. Imaging. 2007;34:463–71. 
8. Hicks RJ, Kalff V, Macmanus MP, Ware RE, 
Mckenzie AF, Matthews JP, et al. The Utility 
of F-FDG PET for Suspected Recurrent Non 
– Small Cell Lung Cancer After Potentially 
Curative Therapy : Impact on Management and 
Prognostic Stratification. 2001;42:10–21. 
9. Dijkman BG, Schuurbiers OCJ, Vriens D, 
Looijen-Salamon M, Bussink J, Timmer-Bonte 
JNH, et al. The role of (18)F-FDG PET in the 
differentiation between lung metastases and 
synchronous second primary lung tumours. Eur. 
J. Nucl. Med. Mol. Imaging. Berlin/Heidelberg: 
Springer-Verlag; 2010;37:2037–47. 
10. Hellwig D, Graeter TP, Ukena D, Groeschel A, 
Sybrecht GW, Schaefers HJ, et al. 18F-FDG 
PET for mediastinal staging of lung cancer: 
which SUV threshold makes sense? J Nucl Med. 
2007;48:1761–6. 
11. Agarwal M, Brahmanday G, Bajaj SK, 
Ravikrishnan KP, Wong C-YO. Revisiting the 
prognostic value of preoperative (18)F-fluoro-
2-deoxyglucose ( (18)F-FDG) positron emission 
tomography (PET) in early-stage (I & II) non-
small cell lung cancers (NSCLC). Eur. J. Nucl. 
Med. Mol. Imaging. 2010;37:691–8. 
12. Liao S, Penney BC, Wroblewski K, Zhang H, 
Simon CA, Kampalath R, et al. Prognostic 
value of metabolic tumor burden on 18F-FDG 
PET in nonsurgical patients with non-small cell 
lung cancer. Eur. J. Nucl. Med. Mol. Imaging. 
2012;39:27–38. 
13. Weber WA. Use of PET for Monitoring Cancer 
Therapy and for Predicting Outcome. J. Nucl. 
Med. 2005;46:983–95. 
14. Hicks RJ. Role of 18F-FDG PET in Assessment 
of Response in Non-Small Cell Lung Cancer. J. 
Nucl. Med. 2009;50:31S–42. 
15. Czernin J, Weber WA, Herschman HR. 
Molecular imaging in the development of cancer 
therapeutics. Annu. Rev. Med. United States; 
2006;57:99–118. 
16. Frank R, Hargreaves R. Clinical biomarkers in 
drug discovery and development. Nat. Rev. Drug 
Discov. England; 2003;2:566–80. 
17. Weber WA. Assessing Tumor Response to 
Therapy. J Nucl Med. 2009;50:1S–10. 
18. Bengtsson T, Hicks RJ, Peterson A, Port RE. 
18F-FDG PET as a surrogate biomarker in non-small 
cell lung cancer treated with erlotinib: newly identified 
lesions are more informative than standardized uptake 
value. J. Nucl. Med. 2012;53:530–7. 
19. Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, 
et al. Standard uptake value and metabolic tumor 
volume of 18F-FDG PET/CT predict short-term 
outcome early in the course of chemoradiotherapy 
in advanced non-small cell lung cancer. Eur. J. 
Nucl. Med. Mol. Imaging. 2011;38:1628. 
20. Thie JA. Understanding the standardized uptake 
value, its methods, and implications for usage. J. 
541106-L-bw-Kaalep
Processed on: 18-3-2020 PDF page: 49
49
CHAPTER 2
Nucl. Med. 2004;45:1431–4. 
21. Weber WA, Petersen V, Schmidt B, Tyndale-
Hines L, Link T, Peschel C, et al. Positron 
emission tomography in non-small-cell lung 
cancer: prediction of response to chemotherapy 
by quantitative assessment of glucose use. J. Clin. 
Oncol. United States; 2003;21:2651–7. 
22. Kelly MD, Declerck JM. SUVref: reducing 
reconstruction-dependent variation in PET SUV. 
EJNMMI Res. 2011;1:16. 
23. Adams MC, Turkington TG, Wilson JM, Wong TZ. 
A systematic review of the factors affecting 
accuracy of SUV measurements. AJR. Am. J. 
Roentgenol. United States; 2010;195:310–20. 
24. Boellaard R. Standards for PET image acquisition 
and quantitative data analysis. J. Nucl. Med. 
2009;50 Suppl 1:11S–20S. 
25. Kinahan PE, Fletcher JW. Positron emission 
tomography-computed tomography standardized 
uptake values in clinical practice and assessing 
response to therapy. Semin. Ultrasound. CT. MR. 
United States; 2010;31:496–505. 
26. Fahey FH, Kinahan PE, Doot RK, Kocak M, 
Thurston H, Poussaint TY. Variability in PET 
quantitation within a multicenter consortium. 
Med. Phys. United States; 2010;37:3660–6. 
27. Beyer T, Czernin J, Freudenberg LS. Variations in 
clinical PET/CT operations: results of an 
international survey of active PET/CT users. J. 
Nucl. Med. United States; 2011;52:303–10. 
28. Graham MM, Badawi RD, Wahl RL. Variations 
in PET/CT methodology for oncologic imaging 
at U.S. academic medical centers: an imaging 
response assessment team survey. J. Nucl. Med. 
2011;52:311–7. 
29. Hristova I, Boellaard R, Vogel W, Mottaghy F, 
Marreaud S, Collette S, et al. Retrospective 
quality control review of FDG scans in the 
imaging sub-study of PALETTE EORTC 62072/
VEG110727: a randomized, double-blind, 
placebo-controlled phase III trial. Eur. J. Nucl. 
Med. Mol. Imaging. 2015;42:848–57. 
30. Boellaard R. Mutatis mutandis: harmonize the 
standard! J. Nucl. Med. 2012;53:1–3. 
31. Buckler AJ, Boellaard R. Standardization of 
quantitative imaging: the time is right, and 
18F-FDG PET/CT is a good place to start. J. 
Nucl. Med. 2011;52:171–2. 
32. Sunderland JJ, Christian PE. Quantitative PET/
CT Scanner Performance Characterization 
Based Upon the Society of Nuclear Medicine 
and Molecular Imaging Clinical Trials Network 
Oncology Clinical Simulator Phantom. J Nucl 
Med. 2015;56:145–52. 
33. Rausch I, Cal-González J, Dapra D, Gallowitsch HJ, 
Lind P, Beyer T, et al. Performance evaluation 
of the Biograph mCT Flow PET/CT system 
according to the NEMA NU2-2012 standard. 
EJNMMI Phys. 2015;2:26. 
34. Lasnon C, Desmonts C, Quak E, Gervais R, 
Do P, Dubos-Arvis C, et al. Harmonizing SUVs in 
multicentre trials when using different generation 
PET systems: Prospective validation in non-small 
cell lung cancer patients. Eur. J. Nucl. Med. Mol. 
Imaging. 2013;40:985–96. 
35. Boellaard R, Delgado-Bolton R, Oyen WJG, 
Giammarile F, Tatsch K, Eschner W, et al. FDG 
PET/CT: EANM procedure guidelines for tumour 
imaging: version 2.0. Eur. J. Nucl. Med. Mol. 
Imaging. 2014;42:328–54. 
36. Delbeke D, Coleman RE, Guiberteau MJ, 
Brown ML, Royal HD, Siegel B a, et al. Procedure 
guideline for tumor imaging with 18F-FDG PET/
CT 1.0. J. Nucl. Med. 2006;47:885–95. 
37. Graham MM, Wahl RL, Hoffman JM, Yap JT, 
Sunderland JJ, Boellaard R, et al. Summary of the 
UPICT protocol for 18F-FDG PET/CT imaging in 
oncology clinical trials. J. Nucl. Med. 2015;56:955–61. 
38. Makris NE, Huisman MC, Kinahan PE, AA,
Boellaard R. Evaluation of strategies towards 
harmonization of FDG PET/CT studies in 
multicentre trials: Comparison of scanner validation 
phantoms and data analysis procedures. Eur. J. Nucl. 
Med. Mol. Imaging. 2013;40:1507–15. 
39. Scheuermann JS, Saffer JR, Karp JS, Levering AM, 
Siegel A. Qualification of PET Scanners for 
Use in Multicenter Cancer Clinical Trials: The 
American College of Radiology Imaging Network 
Experience. J. Nucl. Med. 2010;50:1187–93. 
40. Kinahan P, Wahl R, Shao L, Frank R, Perlman E. 
The QIBA profile for quantitative FDG-PET/CT 
oncology imaging. J. Nucl. Med. 2014;55:1520-. 
41. Boellaard R, Willemsen  a T, Arends B, Visser EP. 
EARL procedure for assessing PET/CT system 
specific patient FDG activity preparations for 
quantitative FDG PET/CT studies. 2013. p. 1–3. 
42. EANM EARL website [Internet]. Available from: 
http://earl.eanm.org
43. Geworski L, Knoop BO, de Wit M, Ivancevic V, 
Bares R, Munz DL. Multicenter Comparison 
of Calibration and Cross Calibration of PET 
Scanners. J. Nucl. Med. 2002;43:635–9.
541106-L-bw-Kaalep
Processed on: 18-3-2020 PDF page: 50
541106-L-bw-Kaalep
Processed on: 18-3-2020 PDF page: 51
Feasibility of state of the art PET/CT 
systems performance harmonisation
Author(s): Andres Kaalep, Terez Sera, Sjoerd Rijnsdorp, Maqsood Yaqub, 
Anne Talsma, Martin A. Lodge, Ronald Boellard
as published in the European Journal of Nuclear Medicine and Molecular Imaging 
(Kaalep et al, 2018)
Chapter 3
541106-L-bw-Kaalep
Processed on: 18-3-2020 PDF page: 52
541106-L-bw-Kaalep
Processed on: 18-3-2020 PDF page: 53
53
3.1 Abstract
Purpose: The objective of this study was to explore the feasibility of harmonising 
performance for PET/CT systems equipped with time-of-flight (ToF) and resolution modelling/
point spread function (PSF) technologies. The second aim was producing a working prototype 
of new harmonising criteria with higher contrast recoveries than current EARL standards using 
various SUV metrics.
Methods: Four PET/CT systems with both ToF and PSF capabilities from 3 major vendors 
were used to acquire and reconstruct images of the NEMA NU2-2007 body phantom filled 
conforming EANM EARL guidelines. A total of 15 reconstruction parameter sets of varying pixel 
size, post filtering and reconstruction type, with 3 different acquisition durations were used 
to compare the quantitative performance of the systems. A target range for recovery curves 
was established such that it would accommodate the highest matching recoveries from all 
investigated systems. These updated criteria were validated on 18 additional scanners from 16 
sites in order to demonstrate the scanners’ ability to meet the new target range.
Results: Each of the four systems was found to be capable of producing harmonising 
reconstructions with similar recovery curves. The 5 reconstruction parameter sets producing 
harmonising results significantly increased SUVmean (25%) and SUVmax (26%) contrast recoveries 
compared with current EARL specifications. Additional prospective validation performed on 18 
scanners from 16 EARL accredited sites demonstrated the feasibility of updated harmonising 
specifications. SUVpeak was found to significantly reduce the variability in quantitative results 
while producing lower recoveries in smaller (≤17 mm diameter) sphere sizes.
Conclusions: Harmonising PET/CT systems with ToF and PSF technologies from different 
vendors was found to be feasible. The harmonisation of such systems would require an update 
to the current multicentre accreditation program EARL in order to accommodate higher 
recoveries. SUVpeak should be further investigated as a noise resistant alternative quantitative 
metric to SUVmax.
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18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and computed 
tomography (CT) hybrid imaging (PET/CT) is an important functional imaging tool being widely 
used for diagnosis, staging and therapy response evaluation in e.g. oncology [1–20]. Combined 
anatomical and functional information can be obtained in one session using hybrid PET/CT. 
In clinical practice, visual inspection of PET/CT images might be sufficient for the purposes of 
staging or restaging [7][21], however PET is a quantitative technique [22–26] and can provide 
more accurate and less observer-dependent metrics for diagnosis, therapy assessment and 
response monitoring using quantitative data in addition to visual interpretation [27]. In 
recent oncological clinical trials quantitative PET/CT data are also used for patient selection, 
stratification and therapy response monitoring. However, variability, reproducibility and 
accuracy of quantitative PET/CT imaging [28–34] have to be considered. Scientific societies 
such as the European Association of Nuclear Medicine (EANM), American College of Radiology 
(ACR), American Association of Physicists in Medicine (AAPM), Radiological Society of North 
America (RSNA) and Society of Nuclear Medicine and Molecular Imaging (SNMMI) are closely 
collaborating to promote standardisation of practices in order to reduce variability of 
quantification in multicentre clinical trials. Initiatives such QIBA-UPICT, SNMMI-CTN and EANM-
EARL are providing quality control programs to assure quantitative comparability [35–40].
High utilization of PET/CT in oncology can be attributed to the availability of 18F-FDG [5,41]. 
Dynamic PET scans and pharmacokinetic modelling to evaluate the rate of glucose metabolism 
of tumour is an excellent method for quantification [27] but the technical impediments such 
as the limited scanner field of view and increased scan acquisition time make it unfeasible for 
routine use [42]. In clinical practice, a simplified uptake metric such as the standard uptake value 
(SUV) [43,44] is therefore most commonly used. While SUV analysis is relatively easy to apply, 
it suffers from multiple technical, physical and biological factors that can significantly affect 
quantification [27]. The required level of harmonisation depends on the intended use of the 
PET study. When the same PET/CT system is used for therapy assessment and based on relative 
changes in SUV before and after therapy, a high reproducibility rather than absolute accuracy 
might be most important. It has been shown that in this case, when the scanner performance 
remains unchanged over time, consistent application of a certain methodology could be 
sufficient [34,45]. However, patients are often scanned on different PET/CT systems, either 
because the scanner had been replaced by a new one, or in different institutions, which makes 
accurate cross-calibration of systems a crucial requirement. Absolute quantitative measures 
(e.g., residual uptake of 18F-FDG after therapy session) are also being used for differentiation 
between malignant and benign lesions, determining prognosis and response monitoring [27]. 
This again requires high reproducibility and comparability of the quantitative data, especially 
in multicentre settings. 
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One of the challenges in PET/CT systems performance harmonisation is the variability 
caused by different PET/CT technologies available in the field. Multicentre standards should 
not be based on the less performing systems; they need to fit with the highest, yet common 
denominator in systems’ performances. Additionally, in case of optimization of PET/CT 
systems performance for lesion detection, a single centre quantification doesn’t necessarily 
coincide with a multicentre one. A particular challenge for recent PET/CT systems resulted 
from the introduction of time-of-flight (ToF) and resolution modelling (point spread function 
(PSF)) capabilities. The latter increased tumour detectability but also caused higher variability 
across centres, since some have and others lack these technologies. Currently a large number 
of the EARL accredited PET/CT systems [46] do not have PSF image reconstruction capabilities. 
However, it is expected that over the next couple of years the majority of the PET/CT systems 
will be equipped with these new reconstruction techniques. 
The aim of this paper is to explore the feasibility of harmonising performance of PET/CT 
systems equipped with the latest PET technologies such as TOF and PSF, which were recently 
commercially released. 
3.3 Materials and methods
3.3.1 PET/CT system selection
Four PET/CT systems equipped with both ToF and PSF capabilities from 3 major vendors 
(General Electric (GE), Siemens and Philips) were selected for this study. Systems included were 
Siemens Biograph mCT (Siemens system 1), Siemens Biograph mCT Flow (Siemens system 2), 
GE Discovery 710 (GE system) and Philips Ingenuity TF 128 (Philips system). The equipment was 
calibrated in accordance with the corresponding manufacturer’s instructions. In addition, 
all systems were participating and accredited in the EANM/EARL 18F-FDG PET/CT accreditation 
program. Detailed specifications for the systems can be found in supplemental table 1 and 
references [47][48][49][50][51].
3.3.2 Phantom experiments
The phantoms and filling procedures used complied with the EANM/EARL guidelines for 
Image Quality QC measurements which need to be performed annually as part of the EANM/
EARL accreditation program [35]. The NEMA NU2-2007 body phantom was used, which is 
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a plastic cylinder in form of a fillable torso cavity, to act as a background compartment. 
It has a 5 cm diameter cylindrical lung insert in the centre and 6 fillable spheres with internal 
diameters of 10 mm, 13 mm, 17 mm, 22 mm, 28 mm and 37 mm, positioned coaxially around 
the lung insert. The lung insert is filled with polystyrene beads in order to mimic lung tissue. 
The phantom background compartment and the spherical inserts were filled with 18F-FDG 
solutions aimed at activity concentrations of 2 kBq/mL and 20 kBq/mL, respectively, at the start 
of the measurements, resulting in a sphere to background activity concentration ratio of 10:1.
3.3.3 Acquisition & reconstruction parameters
In accordance with current EANM/EARL guidelines for 18F-FDG Image Quality QC phantom 
imaging [35], a low dose CT acquisition, followed by an emission scan consisting of two bed 
positions with an acquisition time of 5 minutes per bed position is to be acquired for the 
“image quality” dataset to assess contrast recovery performance. In this study, acquisition 
time of 5 minutes per bed position was selected as the reference for high count statistics. In 
order to investigate the effect of reduced count statistics on contrast recovery, data acquired 
with shorter acquisition times, respectively 2 and 1 minutes per bed position, were collected. 
The GE and Philips systems had list mode data acquisition capability available, which meant 
that only the 5 minute/bed position emission scans were acquired and reconstructions with 
shorter acquisition times were generated retrospectively from the list mode data. On the 
Siemens systems included in this study, multiple shorter emission scans were acquired with 
the phantom left in an unchanged position. In order to facilitate the Siemens Flow system’s 
(Siemens system 2) possibility of performing scanning with continuous table movement, 
instead of a specific bed position scanning duration, table feed speeds of 0.5 mm/s, 1 mm/s 
and 2 mm/s were selected, resulting in similar acquisition times as with the other scanners. 
Reconstructions were performed using the software available on each of the PET/CT systems. 
TOF, PSF, normalisation, randoms, scatter and attenuation corrections were applied and the 
reconstruction parameters were selected to increase overall contrast recovery, meanwhile 
aiming at achieving comparable recovery values across systems (for each sphere). In addition, 
we also considered to achieve comparable recovery values between the spheres to minimize 
severe partial volume effects as well as large Gibbs overshoots. Clinically used and vendor 
recommended reconstruction parameters were applied and varied. 3 iterations with 21 subsets 
were used for Siemens 1 (Biograph mCT) and 2 iterations with 21 subsets for Siemens 2 (mCT 
Flow) reconstruction. For GE - B, D, F and G (Discovery 710) - 2 iterations with 24 subsets 
and VPFXS reconstruction method, while for GE - A, C and E - QCFX reconstruction method, 
with an unknown number of iterations and subsets, was used. For the Philips systems the 
iterations/subsets were 3/33 but these could not be selected prior scanning, neither its values 
retrieved from the DICOM header of the images; BLOB OS TF reconstruction method was used. 
541106-L-bw-Kaalep
Processed on: 18-3-2020 PDF page: 57
57
CHAPTER 3
Different Gaussian filters and pixel sizes within clinically relevant range were also investigated 
in order to study their effects on contrast recovery. Additionally, for the GE system, a 
proprietary reconstruction method, the “Q.Clear”, which uses a Bayesian penalized-likelihood 
reconstruction algorithm, was investigated using different penalization factors (β) and its effect 
on quantitative image quality was evaluated. Due to differences among vendors and models, 
the available reconstruction parameters and their ranges were limited based on availability 
and/or user selectability. In total, 15 reconstruction parameter sets (reconstruction modes) 
were used to assess and compare the quantitative performance of the investigated systems. 
Each reconstruction mode was applied on three different scans, acquired with long (~4 min/
bed for Siemens Flow system; ~5 min/bed for all other systems), medium (~2 min/bed) and 
short (~1 min/bed) frame durations. A summary of the acquisition and reconstruction settings 

















GE - A N/A 200 2.73 3.27 300 120 60
GE - B 0 N/A 2.73 3.27 300 120 60
GE - C N/A 350 2.73 3.27 300 120 60
GE - D 3 N/A 2.73 3.27 300 120 60
GE - E N/A 800 2.73 3.27 300 120 60
GE - F 5 N/A 2.73 3.27 300 120 60
GE - G 6.4 N/A 2.73 3.27 300 120 60
Philips - A N/A N/A 2.00 2.00 301 120 60
Philips - B N/A N/A 4.00 4.00 301 120 60
Siemens 1 - A 0 N/A 2.04 2.00 300 120 60
Siemens 1 - B 0 N/A 1.59 2.00 300 120 60
Siemens 1 - C 3 N/A 2.04 2.00 300 120 60
Siemens 1 - D 5 N/A 2.04 2.00 300 120 60
Siemens 1 - E 6.5 N/A 3.18 2.00 300 120 60
Siemens 2 - A 5 N/A 4.07 5.00 223 111 56
Table 1. Acquisition and reconstruction settings for initial 15 reconstruction modes
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Data reconstructed on the PET/CT were exported to a PC for further analysis using the EARL 
semi-automatic tool [35] designed for quantitative analysis of images of NEMA NU2-2007 body 
phantom, filled conforming EANM/EARL guidelines for 18F-FDG Image Quality QC phantom 
imaging. The software tool requires phantom images in DICOM format and filling data as input, 
and extracts SUV recovery for the spheres, calibration factor for the background compartment 
and standard deviation and coefficient of variation from uniform images of the background. 
SUV recovery coefficient (RC) is defined as the ratio between measured and expected activity 
concentration in each spherical insert. RC values were calculated based on 50% background 
corrected isocontour VOI (RCSUVmean), maximum voxel value included in VOI (RCSUVmax) and 
spherical VOI with a diameter of 12 mm, positioned so to yield the highest uptake (RCSUVpeak) 
[39][35][52].
Prior to further analysis, all data were corrected for system calibration bias in order to be 
able to compare the various reconstruction modes’ impact on RCs and not to be effected by 
inter-scanner calibration errors. For this purpose, to all RCs a correction factor, defined as the 
ratio between expected and measured activity concentration in the corresponding uniform 
background compartment was applied. For the 15 initial reconstruction modes, inter-scanner 
global correction factors ranged from 0.88 to 1.12, with the mean and standard deviation 
being 0.98 and 0.055, respectively. Intra-scanner changes were below 1%. For the 23 additional 
reconstructions, the inter-scanner global correction factors ranged from 0.93 to 1.10 (one 
system, however, showed a correction factor of 0.8), with the mean and standard deviation 
values of 0.99 and 0.055, respectively.
3.3.5 Selection of harmonising reconstruction modes 
The primary objective of this study was to find reconstruction modes providing high, yet 
uniform contrast recoveries within the spheres of the NEMA NU2-2007 body phantom, which 
could be matched across all generations of PET/CT systems currently used in clinical practice – 
which would result in quantitative harmonisation of PET/CT systems. 
RCSUVmean, RCSUVmax and RCSUVpeak curves for all reconstructed phantom images were plotted 
against sphere diameters (figure 1) and characterised using visual and quantitative analysis, for 
which the applied metrics are summarised in table 2. Reconstruction modes with higher RCs 
than current EARL specifications, as well as tightly grouped and stable RCSUVmean and RCSUVmax 
curves, were sought for harmonisation purposes.
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Metric Description of metric
SUVmean
Ratio of image derived average radioactivity concentration within a region of interest and the 
whole body concentration of the injected radioactivity 
SUVmax
Ratio of image derived maximum (single pixel) radioactivity concentration within a region of 
interest and the whole body concentration of the injected radioactivity
SUVpeak
Ratio of image derived average radioactivity concentration within a 12 mm diameter spherical 
volume within the region of interest, positioned to yield the highest uptake, and the whole 
body concentration of the injected radioactivity
RC Recovery Coefficient - the ratio between image derived and expected activity concentration
MCR*
Mean Contrast Recovery - mean RC of all spheres in corresponding reconstruction mode’s 
long duration acquisition. Parameter is indicative of reconstruction mode's overall contrast 
recovery potential.
CoVMCR Coefficient of Variation (SD/mean*100, %) of a group of MCR values. Parameter is indicative of RC curves' alignment within a group.
CRVmedium*
Contrast Recovery Variability - Mean deviation of medium duration acquisition spheres' RCs 
from the corresponding values of long duration aquisition.
CRVshort*
Contrast Recovery Variability - Mean deviation of short duration acquisition spheres' RCs from 
the corresponding values of long duration aquisition.
CoVBG*
Coefficient of Variation (SD/mean *100, %) of measured activity concentration within the 
uniform background compartment of the phantom. Parameter is indicative of the noise 
present in the images.
Curvature
Long acquisition duration root-mean-square deviation of spheres' RC values from RC value 
of the largest (37 mm) sphere. Parameter characterises the deviation of smaller spheres' RC 
values which usually cause the RC-object size relation to assume a curved shape.
Absolute error
Long acquisition duration root-mean-square deviation of spheres' RC values from unity. 
The parameter characterises the reconstruction mode's ability to report accurate activity 
concentration values.
Curvature (excl. 
10 mm sphere) Same as „curvature“ but excluding the smallest (10 mm) sphere.
Absolute error 
(excl. 10 mm 
sphere)
Same as „absolute error“ but excluding the smallest (10 mm) sphere.
Table 2. Description of quantitative metrics used.
*Quantitative metrics that were retrospectively used to determine harmonising cut-off criteria
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Fig. 1. RC curves derived from 15 initial reconstruction modes using SUVmean (a), SUVmax (b) 
and SUVpeak (c) quantitative metrics. Only long acquisition time frame curves are displayed. GE 
(Q.Clear) – blue dashed lines, GE (non-Q.Clear) – blue solid lines, Philips – red solid lines, Siemens 
1 – orange solid lines, Siemens 2 – green solid lines, current EARL specifications – black solid lines.
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The harmonising reconstruction modes were selected by simultaneously analysing quantitative 
characteristics of the reconstruction modes along with visual appearance of the RC curves. 
Following considerations were kept in mind while determining feasible reconstruction modes 
– (1) the proposed harmonising specifications should provide an increase over the current EARL 
compliant RC values, (2) the bandwidth of RCs should be similar to the current Earl specification 
limits and (3) the harmonising RC curves should not demonstrate major overshoots (=upward 
bias) due to Gibbs artefacts. While the harmonising reconstruction modes were selected based 
on the abovementioned considerations, quantitative cut-off criteria were retrospectively 
determined and stated in Table 9 based on the bandwidth and characteristics of harmonising 
reconstruction modes. Performances of the candidate reconstruction modes were compared 
with the initial group of reconstructions as well as current EARL accreditation specifications. 
3.3.6 Mean Contrast Recovery (MCR)
Mean contrast recovery (MCR) was calculated in order to evaluate overall contrast recovery 
potential of a reconstruction mode while Coefficient of Variation of the MCR parameter 
(CoVMCR) was used to characterise agreement among various reconstruction modes’ RC 
curves. Increased coinciding MCR and reduced CoVMCR values were preferred.
3.3.7 Contrast Recovery Variability (CRV)
Contrast Recovery Variability (CRVmedium and CRVshort) parameters were used to evaluate a 
reconstruction mode’s ability to produce consistent results in case of reduced count statistics. 
In order to achieve it, RCs of short and medium time frame acquisitions were compared to 
the long acquisition’s corresponding spheres’ RCs and relative differences calculated.  Lower 
values were deemed preferable as being indicative of reconstruction mode’s stability and 
reduced variability in noisy environments. 
3.3.8 Noise
Image noise was quantitatively evaluated by measuring the Coefficient of Variation (%, SD/
Mean*100) in the uniform background compartment (CoVBG) for each reconstruction mode 
and acquisition time frame. CoVBG cut-off limit of 15%, based on the existing EARL guideline 
and UPICT [35,37,40], was implemented to determine suitable reconstruction modes for 
harmonisation. Reconstruction modes providing lower noise images were deemed preferable.
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Fig. 2. RC curves derived from suggested harmonising reconstruction modes using SUVmean (a), 
SUVmax (b) and SUVpeak (c) quantitative metrics along with current EARL and possible new 
specifications. Only long acquisition time frame curves are displayed. GE (Q.Clear) – blue dashed 
lines, GE (non-Q.Clear) – blue solid lines, Philips – red solid lines, Siemens 1 – orange solid lines, 
Siemens 2 – green solid lines, current EARL specifications – black solid lines, possible new EARL 
specifications – black dashed lines.
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3.3.9 Curvature and absolute error
Curvature and absolute error parameters were used to evaluate RC variability and absolute 
accuracy of RC measurements due to changes in sphere/lesion size. Reduced values were 
preferable but similar magnitude across systems/reconstructions was given priority.
3.3.10 Visual analysis
Visual analysis of the RC curves was used to identify reconstruction modes that exhibited 
abnormal behaviour or localised variations, such as exaggerated Gibbs artefacts, that were not 
identified by the previously described quantitative parameters. The reconstruction modes, 
which were considered for harmonisation based on SUVmean and SUVmax performance, 
were also used to develop provisional specifications for SUVpeak.
3.3.11 Validation of reconstruction modes for harmonisation
In order to prospectively evaluate the reproducibility and inter-scanner variability of the 
proposed reconstruction modes for harmonisation, 16 EARL accredited facilities, equipped 
with current generation PET/CT systems, participated in the study and provided the 
requested reconstructions from independent phantom acquisitions applying acquisition and 
reconstruction parameters (supplemental table 2) identical or similar to the reconstructions 
proposed for harmonisation purposes. Data received from the centres was analysed in the 
same way as the reconstructions in the pilot study.
3.4 Results
3.4.1 New specifications proposed for harmonisation
Analysis of the initial 15 reconstruction modes resulted in 5 reconstruction modes, which 
produced highest uniform contrast recoveries and were feasible for all of the investigated 
systems considering SUVmean and SUVmax (Philips - B, GE – E, GE - F, Siemens 1 – D and Siemens 
2 – A), to be considered for harmonisation. In order to accommodate unavoidable inter-scanner 
variability and reproducibility errors due to equipment calibration and user inaccuracy, all of the 
RC ranges were expanded to be proportional (i.e. using the same bandwidth of performance, 
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but taking into account increased contrast recovery) to current EARL specifications for sphere 
recoveries. Specifications, based on the current findings, proposed for harmonisation along 
with current EARL specifications are presented in Table 13. Bandwidths for proposed and 
current EARL specifications as well as the RC curves derived from the 5 reconstruction modes are 
presented in figure 2. For the provisional SUVpeak specifications, average sphere recoveries of 
the 5 reconstruction modes and a bandwidth of ± 2 standard deviations was used. Additionally, 
recovery coefficients are plotted as function of background noise for each sphere and per 
SUVmetric (presented in supplemental figures 4-6). Axial slices of the phantom data from the 5 
harmonising reconstructions are shown in supplemental figure 7.
3.4.2 Mean Contrast Recovery (MCR)
SUVmean and SUVmax RC curves vary substantially among different systems and 
reconstruction modes as seen in Figure 1 and Tables 3 and 4. The reconstruction mode showing 
the lowest recoveries (Siemens 1 – E) produced a SUVmean MCR value of 0.714 and SUVmax MCR 
of 0.948 while for the highest recovery reconstruction mode (Siemens 1 – A), the corresponding 
values were 1.09 and 1.56 – a difference of more than 50%. SUVpeak MCR values were found to 
be between 0.754 and 0.929. CoVMCR values for the 15 reconstruction modes were 12.4% and 
15.4% for SUVmean and SUVmax, respectively, while for SUVpeak, CoVMCR was 6.0%.
For the 5 reconstruction modes proposed for harmonisation, the range of MCR values 
were 0.770 – 0.816 and 1.01 – 1.09 for SUVmean and SUVmax, respectively. The harmonising 
reconstruction modes produced SUVpeak MCR values in the range of 0.784 – 0.823. CoVMCR 
values for SUVmean, SUVmax and SUVpeak were 2.2%, 2.9% and 2.2%, respectively. 
3.4.3 Contrast Recovery Variability (CRV)
The initial 15 reconstruction modes demonstrated variable sensitivity in function of count 
statistics. The expected increase in variability with decrease in count statistics was observed 
in all reconstruction modes by comparing CRVmedium and CRVshort values (Tables 3-5). The 
CRVmedium results for SUVmean, SUVmax and SUVpeak ranged from 2.4% to 8.4%, 2.7% to 
17.8% and 1.6% to 4.5%, respectively. The CRVshort results for SUVmean, SUVmax and SUVpeak 
ranged from 2.3% to 14.5%, 4.9% to 20.4% and 2.7% to 6.3%, respectively. 
For the 5 reconstruction modes proposed for harmonisation, the CRVmedium results for 
SUVmean, SUVmax and SUVpeak ranged from 2.7% to 5.3%, 3.7% to 8.0% and 2.8% to 3.0%, 
respectively. The CRVshort results for SUVmean, SUVmax and SUVpeak ranged from 2.3% to 
6.2%, 5.2% to 9.2% and 2.9% to 5.8%, respectively.
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The CoVBG values are summarised in supplemental figure 8. The average CoVBG of all 
reconstruction modes with long time frame was 12.6%. For medium and short acquisition 
times, the corresponding values were 19.7% and 27.0%, respectively. The selected reconstruction 
modes for harmonisation purposes produced average CoVBG values of 9.4%, 14.0% and 18.4% 
for long, medium and short acquisition time frames, respectively.
3.4.5 Curvature and absolute error
Curvatures for the initial 15 reconstruction modes were in the ranges of 0.031 – 0.269, 
0.076 – 0.290 and 0.305 – 0.413 for SUVmean, SUVmax and SUVpeak, respectively. For the 5 
reconstruction modes suggested for harmonisation the SUVmean, SUVmax and SUVpeak 
curvatures were in the ranges of 0.197 – 0.236, 0.212 – 0.267 and 0.350 – 0.404, respectively.
Absolute errors for the initial 15 reconstruction modes were in the ranges of 0.053 – 0.329, 
0.157 – 0.566 and 0.232 – 0.367 for SUVmean, SUVmax and SUVpeak, respectively. For the 5 
reconstruction modes selected for harmonisation, the SUVmean, SUVmax and SUVpeak 
curvatures ranged between 0.222 – 0.277, 0.170 – 0.232 and 0.291 – 0.346, respectively.
3.4.6 Visual analysis
Significant variations in investigated RC curves’ shapes and positions of Siemens 1 - A, B, C, 
GE - A, B, C, D and Philips – A reconstruction modes were noticed when compared with other 
systems or acquisition times and considered unsuitable for harmonisation.
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GE - A 0.956 5.0% 6.8% 0.031 0.053 0.023 0.040
GE - B 0.903 8.4% 8.7% 0.139 0.147 0.022 0.050
GE - C 0.887 6.7% 6.4% 0.109 0.140 0.025 0.077
GE - D 0.859 6.3% 6.6% 0.168 0.188 0.053 0.092
GE - E 0.806 5.2% 6.2% 0.218 0.253 0.075 0.134
GE - F 0.770 5.3% 5.3% 0.228 0.277 0.120 0.183
GE - G 0.725 3.8% 4.9% 0.253 0.321 0.147 0.228
Philips - A 0.845 3.3% 4.2% 0.149 0.192 0.088 0.134
Philips - B 0.800 2.7% 2.3% 0.236 0.271 0.124 0.165
Siemens 1 - A 1.086 6.0% 14.5% 0.097 0.117 0.108 0.125
Siemens 1 - B 1.038 3.8% 12.5% 0.072 0.076 0.071 0.081
Siemens 1 - C 0.952 3.3% 8.3% 0.111 0.101 0.048 0.043
Siemens 1 - D 0.816 2.9% 5.1% 0.197 0.222 0.097 0.138
Siemens 1 - E 0.714 2.4% 4.0% 0.269 0.329 0.166 0.238
Siemens 2 - A 0.804 3.0% 4.4% 0.203 0.238 0.100 0.150
Min 0.714 2.4% 2.3% 0.031 0.053 0.022 0.040
Max 1.086 8.4% 14.5% 0.269 0.329 0.166 0.238
Average 0.864 4.5% 6.7% 0.165 0.195 0.085 0.125
COVMCR 12.4%
Table 3. Analysis results of 15 initial reconstruction modes using SUVmean quantitative metric. 
Values found to be outside of acceptable range during retrospective quantitative analysis, are 
coloured red.
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GE - A 1.245 17.8% 20.4% 0.081 0.255 0.089 0.265
GE - B 1.201 11.9% 19.7% 0.160 0.236 0.052 0.257
GE - C 1.142 12.9% 15.1% 0.076 0.157 0.036 0.172
GE - D 1.139 10.6% 15.8% 0.181 0.194 0.047 0.200
GE - E 1.036 7.2% 7.7% 0.212 0.178 0.041 0.119
GE - F 1.013 8.0% 9.2% 0.235 0.170 0.085 0.099
GE - G 0.951 5.5% 6.6% 0.274 0.203 0.129 0.094
Philips - A 1.146 7.2% 15.0% 0.176 0.204 0.103 0.218
Philips - B 1.061 3.7% 5.2% 0.267 0.232 0.150 0.197
Siemens 1 - A 1.555 10.1% 20.3% 0.126 0.566 0.139 0.574
Siemens 1 - B 1.477 8.0% 19.1% 0.116 0.487 0.112 0.505
Siemens 1 - C 1.325 5.4% 12.5% 0.148 0.346 0.104 0.375
Siemens 1 - D 1.094 3.9% 7.9% 0.218 0.179 0.080 0.165
Siemens 1 - E 0.948 2.7% 4.9% 0.290 0.199 0.145 0.084
Siemens 2 - A 1.045 3.7% 5.4% 0.246 0.184 0.104 0.138
Min 0.948 2.7% 4.9% 0.076 0.157 0.036 0.084
Max 1.555 17.8% 20.4% 0.290 0.566 0.150 0.574
Average 1.159 7.9% 12.3% 0.187 0.253 0.094 0.231
COVMCR 15.4%  
Table 4. Analysis results of 15 initial reconstruction modes using SUVmax quantitative metric. 
Values found to be outside of acceptable range during retrospective quantitative analysis, are 
coloured red.
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GE - A 0.848 3.9% 3.7% 0.334 0.287 0.187 0.153
GE - B 0.833 3.4% 5.7% 0.381 0.310 0.237 0.179
GE - C 0.840 2.3% 3.6% 0.359 0.302 0.211 0.166
GE - D 0.823 3.9% 6.3% 0.389 0.320 0.248 0.191
GE - E 0.821 2.9% 4.1% 0.400 0.339 0.250 0.203
GE - F 0.784 3.3% 5.8% 0.404 0.346 0.272 0.223
GE - G 0.757 3.1% 5.9% 0.413 0.367 0.287 0.248
Philips - A 0.874 3.2% 3.4% 0.328 0.281 0.192 0.161
Philips - B 0.796 2.8% 2.9% 0.383 0.341 0.263 0.229
Siemens 1 - A 0.901 4.5% 6.3% 0.305 0.232 0.148 0.090
Siemens 1 - B 0.929 1.6% 4.2% 0.325 0.240 0.154 0.103
Siemens 1 - C 0.872 3.3% 5.0% 0.308 0.251 0.151 0.107
Siemens 1 - D 0.823 3.0% 4.5% 0.350 0.291 0.204 0.155
Siemens 1 - E 0.754 3.9% 2.7% 0.382 0.346 0.255 0.226
Siemens 2 - A 0.789 2.9% 4.9% 0.355 0.323 0.240 0.214
Min 0.754 1.6% 2.7% 0.305 0.232 0.148 0.090
Max 0.929 4.5% 6.3% 0.413 0.367 0.287 0.248
Average 0.830 3.2% 4.6% 0.361 0.305 0.220 0.177
COVMCR 6.0%
Table 5. Analysis results of 15 initial reconstruction modes using SUVpeak quantitative metric.
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GE - E 0.806 5.2% 6.2% 0.218 0.253 0.075 0.134
GE - F 0.770 5.3% 5.3% 0.228 0.277 0.120 0.183
Philips - B 0.800 2.7% 2.3% 0.236 0.271 0.124 0.165
Siemens 1 - D 0.816 2.9% 5.1% 0.197 0.222 0.097 0.138
Siemens 2 - A 0.804 3.0% 4.4% 0.203 0.238 0.100 0.150
Min 0.770 2.7% 2.3% 0.197 0.222 0.075 0.134
Max 0,816 5.3% 6.2% 0.236 0.277 0.124 0.183
Average 0.799 3.8% 4.6% 0.216 0.252 0.103 0.154
COVMCR 2.2%
EARL min 0.570 N/A N/A 0.282 0.466 0.198 0.393
EARL max 0.710 N/A N/A 0.277 0.342 0.176 0.251
Earl Average 0.640 N/A N/A 0.279 0.403 0.187 0.321
Table 6. Results of the analysis of 5 reconstruction modes considered for harmonisation using 
SUVmean quantitative metric.
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GE - E 1.036 7.2% 7.7% 0.212 0.178 0.041 0.119
GE - F 1.013 8.0% 9.2% 0.235 0.170 0.085 0.099
Philips - B 1.061 3.7% 5.2% 0.267 0.232 0.150 0.197
Siemens 1 - D 1.094 3.9% 7.9% 0.218 0.179 0.080 0.165
Siemens 2 - A 1.045 3.7% 5.4% 0.246 0.184 0.104 0.138
Min 1.013 3.7% 5.2% 0.212 0.170 0.041 0.099
Max 1.094 8.0% 9.2% 0.267 0.232 0.150 0.197
Average 1.050 5.3% 7.1% 0.236 0.189 0.092 0.144
COVMCR 2.9%  
EARL min 0.730 N/A N/A 0.347 0.355 0.220 0.237
EARL max 0.970 N/A N/A 0.339 0.236 0.176 0.121
Earl Average 0.850 N/A N/A 0.342 0.277 0.198 0.142
Table 7. Results of the analysis of 5 reconstruction modes considered for harmonisation using 
SUVmax quantitative metric.
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Table 8. Results of the analysis of 5 reconstruction modes considered for harmonisation using 
SUVpeak quantitative metric.










GE - E 0.821 2.9% 4.1% 0.400 0.339 0.250 0.203
GE - F 0.784 3.3% 5.8% 0.404 0.346 0.272 0.223
Philips - B 0.796 2.8% 2.9% 0.383 0.341 0.263 0.229
Siemens 1 - D 0.823 3.0% 4.5% 0.350 0.291 0.204 0.155
Siemens 2 - A 0.789 2.9% 4.9% 0.355 0.323 0.240 0.214
Min 0.784 2.8% 2.9% 0.350 0.291 0.204 0.155
Max 0.823 3.3% 5.8% 0.404 0.346 0.272 0.229
Average 0.803 3.0% 4.4% 0.378 0.328 0.246 0.205
COVMCR 2.2%  
Table 9. Retrospectively determined quantitative cut-off criteria for the harmonising reconstructions.
SUVmean SUVmax
MCR ±11% (0.77-0.96) ±13% (1.01-1.31)
CRVmedium 6% 8%
CRVshort 7% 9%
Visual analysis No excessive Gibbs and partial volume artefacts 
Noise Background CoV ≤15% (high statistics acquisition)
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Ingenuity 1 0.820 N/A N/A 0.213 0.249 0.106 0.145
Ingenuity 2 0.694 N/A N/A 0.276 0.365 0.164 0.263
mCT Flow 1 0.691 N/A N/A 0.303 0.368 0.196 0.270
mCT Flow 2 0.711 N/A N/A 0.298 0.339 0.190 0.242
mCT Flow 3 0.816 N/A N/A 0.193 0.231 0.079 0.136
mCT 1 0.847 N/A N/A 0.176 0.194 0.080 0.112
mCT 2 0.786 N/A N/A 0.194 0.250 0.115 0.181
mCT 3 0.825 N/A N/A 0.188 0.208 0.113 0.142
mCT 4 0.765 N/A N/A 0.174 0.262 0.091 0.195
mCT 5 0.786 N/A N/A 0.195 0.245 0.119 0.179
mCT 6 0.811 N/A N/A 0.136 0.207 0.078 0.161
Discovery 710 1 0.847 N/A N/A 0.153 0.182 0.079 0.120
Discovery 710 2 0.793 N/A N/A 0.217 0.254 0.129 0.174
Discovery 710 1 Q.Clear 1 0.887 N/A N/A 0.120 0.145 0.027 0.074
Discovery 710 2 Q.Clear 2 0.817 N/A N/A 0.211 0.236 0.110 0.146
Discovery 710 3 Q.Clear 3 0.895 N/A N/A 0.121 0.144 0.042 0.073
GE Discovery MI 1 0.794 N/A N/A 0.150 0.228 0.099 0.182
GE Discovery MI 2 0.813 N/A N/A 0.171 0.214 0.102 0.155
GE Discovery MI 1 Q.Clear 1 0.857 N/A N/A 0.081 0.151 0.055 0.129
GE Discovery MI 2 Q.Clear 2 0.869 N/A N/A 0.118 0.156 0.039 0.096
GE Discovery IQ 1 0.817 N/A N/A 0.219 0.244 0.077 0.123
GE Discovery IQ 1 Q.Clear 1 0.818 N/A N/A 0.221 0.246 0.069 0.118
Vereos 1 0.757 N/A N/A 0.191 0.277 0.087 0.195
Min 0.691   0.081 0.144 0.027 0.073
Max 0.895   0.303 0.368 0.196 0.270
Average 0.805   0.188 0.235 0.098 0.157
COVMCR 6.6%
Table 10. Analysis results of 23 additional reconstructions using SUVmean quantitative metric.
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Ingenuity 1 1.094 N/A N/A 0.278 0.264 0.143 0.228
Ingenuity 2 0.917 N/A N/A 0.334 0.288 0.188 0.167
mCT Flow 1 0.911 N/A N/A 0.347 0.270 0.207 0.159
mCT Flow 2 0.943 N/A N/A 0.350 0.234 0.187 0.109
mCT Flow 3 1.071 N/A N/A 0.237 0.211 0.110 0.179
mCT 1 1.118 N/A N/A 0.185 0.179 0.057 0.179
mCT 2 1.038 N/A N/A 0.173 0.140 0.065 0.108
mCT 3 1.098 N/A N/A 0.168 0.148 0.082 0.151
mCT 4 1.019 N/A N/A 0.160 0.130 0.041 0.082
mCT 5 1.033 N/A N/A 0.176 0.127 0.067 0.092
mCT 6 1.067 N/A N/A 0.113 0.107 0.033 0.105
Discovery 710 1 1.139 N/A N/A 0.151 0.176 0.051 0.188
Discovery 710 2 1.045 N/A N/A 0.213 0.168 0.086 0.130
Discovery 710 1 Q.Clear 1 1.172 N/A N/A 0.085 0.189 0.054 0.207
Discovery 710 2 Q.Clear 2 1.049 N/A N/A 0.204 0.172 0.064 0.131
Discovery 710 3 Q.Clear 3 1.154 N/A N/A 0.114 0.184 0.042 0.200
GE Discovery MI 1 1.055 N/A N/A 0.105 0.100 0.032 0.095
GE Discovery MI 2 1.066 N/A N/A 0.179 0.142 0.065 0.125
GE Discovery MI 1 Q.Clear 1 1.119 N/A N/A 0.040 0.123 0.017 0.108
GE Discovery MI 2 Q.Clear 2 1.124 N/A N/A 0.107 0.157 0.039 0.168
GE Discovery IQ 1 1.102 N/A N/A 0.255 0.240 0.047 0.201
GE Discovery IQ 1 Q.Clear 1 1.083 N/A N/A 0.234 0.219 0.052 0.177
Vereos 1 1.029 N/A N/A 0.230 0.176 0.074 0.115
Min 0.911   0.040 0.100 0.017 0.082
Max 1.172   0.350 0.288 0.207 0.228
Average 1.063   0.193 0.180 0.078 0.148
COVMCR 6.3%
Table 11. Analysis results of 23 additional reconstructions using SUVmax quantitative metric.
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Ingenuity 1 0.789 N/A N/A 0.376 0.341 0.246 0.218
Ingenuity 2 0.736 N/A N/A 0.405 0.383 0.284 0.267
mCT Flow 1 0.737 N/A N/A 0.439 0.390 0.324 0.280
mCT Flow 2 0.750 N/A N/A 0.476 0.379 0.353 0.263
mCT Flow 3 0.797 N/A N/A 0.393 0.328 0.274 0.217
mCT 1 0.858 N/A N/A 0.348 0.282 0.214 0.162
mCT 2 0.812 N/A N/A 0.347 0.302 0.225 0.188
mCT 3 0.847 N/A N/A 0.365 0.281 0.242 0.169
mCT 4 0.781 N/A N/A 0.326 0.313 0.198 0.192
mCT 5 0.803 N/A N/A 0.355 0.304 0.243 0.199
mCT 6 0.827 N/A N/A 0.297 0.269 0.184 0.163
Discovery 710 1 0.829 N/A N/A 0.357 0.301 0.234 0.188
Discovery 710 2 0.794 N/A N/A 0.398 0.342 0.274 0.227
Discovery 710 1 Q.Clear 1 0.867 N/A N/A 0.372 0.294 0.231 0.171
Discovery 710 2 Q.Clear 2 0.824 N/A N/A 0.413 0.344 0.276 0.221
Discovery 710 3 Q.Clear 3 0.884 N/A N/A 0.370 0.298 0.212 0.166
GE Discovery MI 1 0.797 N/A N/A 0.351 0.313 0.233 0.202
GE Discovery MI 2 0.819 N/A N/A 0.375 0.308 0.237 0.180
GE Discovery MI 1 Q.Clear 1 0.838 N/A N/A 0.328 0.285 0.200 0.166
GE Discovery MI 2 Q.Clear 2 0.859 N/A N/A 0.356 0.294 0.202 0.157
GE Discovery IQ 1 0.814 N/A N/A 0.407 0.342 0.263 0.210
GE Discovery IQ 1 Q.Clear 1 0.831 N/A N/A 0.412 0.336 0.258 0.199
Vereos 1 0.803 N/A N/A 0.381 0.320 0.251 0.199
Min 0.736   0.297 0.269 0.184 0.157
Max 0.884   0.476 0.390 0.353 0.280
Average 0.813   0.376 0.320 0.246 0.200
COVMCR 4.7%  
Table 12. Analysis results of 23 additional reconstructions using SUVpeak quantitative metric.
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Current EARL RC bandwidth Proposed RC bandwidth
SUVmean SUVmax SUVpeak SUVmean SUVmax SUVpeak
37 0.76-0.89 0.95-1.16 N/A 0.85-1,00 1.05-1.29 0.99-1.07
28 0.72-0.85 0.91-1.13 N/A 0.82-0.97 1.01-1.26 0.95-1.07
22 0.63-0.78 0.83-1.09 N/A 0.80-0.99 1.01-1.32 0.90-1.09
17 0.57-0.73 0.73-1.01 N/A 0.76-0.97 1.00-1.38 0.75-0.99
13 0.44-0.60 0.59-0.85 N/A 0.63-0.86 0.85-1.22 0.45-0.69
10 0.27-0.43 0.34-0.57 N/A 0.39-0.61 0.52-0.88 0.27-0.41
Table 13. SUVmean, SUVmax and SUVpeak specifications proposed for harmonisation along with 
current EARL specifications.
Fig. 3. RC curves derived from additional reconstructions using SUVmean (a), SUVmax (b) and 
SUVpeak (c) quantitative metrics along with proposed new specifications. GE (Q.Clear) – blue 
dashed lines, GE (non-Q.Clear) – blue solid lines, Philips – red solid lines, Siemens – orange solid 
lines, possible new EARL specifications – black dashed lines. 
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16 EARL accredited sites participated in the prospective evaluation of the newly proposed 
specifications for harmonisation and performed reconstructions according to instructions 
provided. Data received included 23 distinctive reconstructions from 3 GE Discovery 710 
systems, 2 Philips Ingenuity systems, 6 Siemens mCT systems, 3 Siemens mCT Flow systems, 
1 GE Discovery IQ system, 2 GE Discovery MI systems and 1 Philips Vereos system. RC curves 
derived from the 18 systems along with proposed new harmonising specifications can be seen 
in figure 3. For SUVmean, 16 out of 138 analysed spheres produced RC values outside of the 
suggested accreditation interval, while for SUVmax and SUVpeak, the number of outliers was 12. 
Quantitative results describing additional reconstructions can be found in Tables 10-12.
3.5 Discussion
The SUVmean and SUVmax RC curves of the initial 15 reconstruction modes vary significantly, 
even within one system. This reflects the high degree of variability that could be introduced 
into quantitative PET with variation in reconstruction settings. The selection of harmonising 
reconstruction modes and the validation which followed on additional reconstructions, 
demonstrated that the variability can be reduced to acceptable limits. 
The acquisition time of 5 minutes per bed position specified in the current EARL accreditation 
settings, while characterising system performance in high statistics scenario, may not provide 
an accurate representation of the reconstruction mode’s performance in clinical setting. 
Therefore, the observation of reduced CRVmedium and CRVshort in reconstruction modes for 
harmonisation is important since the acquisition times when utilising new PET/CT systems 
are routinely reduced to 2 minutes or less per bed position.
Significant increase in both SUVmean and SUVmax MCR values was observed in the 
reconstruction modes proposed for harmonisation compared to the corresponding current 
EARL specifications. The trend is in agreement with results recently published by Sunderland 
et al demonstrating that high-end PET/CT systems are having significantly increased 
SUVmax values in anthropomorphic phantom scans [53]. The metrics for all of the spheres 
demonstrated a noticeable increase, however for the smaller spheres (≤ 17 mm) the effect 
was relatively stronger. This could be explained by the so called Gibbs artefact which produces 
an overshoot of measured activity at the edges of the spheres, becoming more dominant at 
smaller sizes, also described by Lasnon et al [54]. To some extent the effect can be considered 
beneficial, compensating for the inherently lower recoveries seen in the smaller spheres. 
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It should however be noticed that with the use of resolution modelling (PSF) without any or 
with minimal post filtering applied, the overshoot could introduce significant positive SUV 
bias, in particular when using SUVmax. Methods like regularized (MAP) reconstruction with 
a regularizing prior (such as Q.Clear implemented by GE) can also be used to suppress Gibbs 
artefacts and were therefor also considered in this study.
The increased SUVmean and SUVmax recoveries seen in the proposed reconstruction modes 
for harmonisation would significantly reduce the gap that exists today between standardised 
quantitative reconstruction protocols used in multicentre settings and the locally developed 
non-standard protocols for lesion detection and general visual assessment – both of which 
are used in parallel in many nuclear medicine departments. Close agreement between the two 
could lead to the adoption of a single reconstruction mode that would provide standardised 
SUV data while maintaining increased lesion detectability.
In the reconstruction modes identified as suitable candidates for harmonisation, a relatively 
higher increase was found in the recoveries of smaller spheres. This would lead to more “flat” 
RC curves, making subsequent quantitative analysis less dependent on lesion size. With the 
proposed reconstruction modes, the recoveries remained largely size-independent for ≥17 
mm diameter lesions. Moreover, it is important to notice that a possible new harmonising 
standard for systems with PSF implies SUVmax recoveries to exceed 1.0. This suggests that 
if SUVmax remains the de facto field standard for PET/CT quantification, one should accept a 
positive bias of about 10 to 25% for larger homogeneous objects (≥17 mm diameter).
For both SUVmean and SUVmax the proposed reconstruction modes for harmonisation 
yielded promising results. The two largest spheres (28 mm diameter, 37 mm diameter) showed 
excellent agreement across all systems for both SUVmean and SUVmax. Even though there 
isn’t enough data for a reproducibility assessment, it can be predicted that a harmonising 
performance bandwidth is feasible for the next generation of PET/CT systems. The results 
from prospective validation using additional reconstructions will be further improved in the 
EARL accreditation process, where the centres will be guided to optimise their reconstruction 
settings in order to meet the new specifications.
As the harmonising RCs for SUVmean, SUVmax and SUVpeak all demonstrated a noticeable 
curve, the curvature and absolute error parameters exhibited increased or similar values with 
the initial reconstruction modes. Calculations excluding the smallest sphere demonstrated 
much better performance which illustrated the high impact the smallest sphere has, which 
led to a significant decrease in the RCs range.
The utility of SUVpeak was investigated as being a possible metric for standardised 
quantification. A recent prospective repeatability study by Kramer et al. [55] demonstrated 
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the robustness of using SUVpeak in non–small cell lung cancer patients. As previously shown 
by Makris et al. [56], and presented on supplemental figures 4-6,  SUVpeak is significantly less 
sensitive to changes in reconstruction parameters and acquisition durations than SUVmean or 
SUVmax. The difference is mostly prominent in the initial group of 15 relatively loosely selected 
reconstruction modes, while within the 5 reconstructions for harmonisation and 23 additional 
ones, the difference became less apparent. On the other hand, the benefits of SUVpeak were 
offset by its consistently low recoveries for spheres with ≤17 mm diameter and therefore low MCR, 
which is comparable to that of SUVmean but significantly (20-40 %) lower than that of SUVmax. 
This is due to peak VOI size approaching or even exceeding the size of the sphere, therefore 
missing some of the active volume. If this issue could be addressed by, for example reducing 
the SUVpeak VOI size, SUVpeak may be become an effective alternative to SUVmax, especially if 
quantitative comparison among reconstructions of unknown origin or non-harmonised PET/CT 
systems is desired. Harmonisation among systems remains necessary in order to enable reliable 
use of SUVmax. Further studies are needed in order to explore the optimal peak VOI diameter 
maintaining noise cancelling effects, while producing higher, yet harmonised recoveries.
An alternative to the described methodology of achieving harmonised recoveries, such as 
suggested in this paper, could be to gradually increase the post smoothing on high recovery 
PET data until harmonized RC-s are obtained (supplemental figures 9-11). Such a method is 
available on some systems and previously validated by Lasnon et al [54]. Potentially a post-
smoothing feature on a workstation could be used for this purpose. This could result in higher 
recoveries and may reduce noise and Gibbs artefacts to acceptable levels for multicentre 
harmonisation. However, when offline post-smoothing needs to be applied to a dataset 
in order for it to achieve quantitative harmonisation, the filter information for the specific 
system always needs to accompany the PET data and extra care be taken that the filter be 
actually applied and clearly reported every time when required.
3.5.1 Limitations and future directions
Quantification of PET images is affected by uncertainties derived from reconstruction 
settings as well as global system (cross-) calibration. In this study the experimental data were 
corrected for global calibration errors, but in clinical practice both effects should be taken into 
consideration. Therefore, an accurate system calibration remains of utmost importance for all 
PET/CT systems used for quantification in order to keep the uncertainties as low as possible.
The phantom experiments conducted were sensitive to measurement uncertainties of dose 
calibrators and human error during the phantom preparation phase. The uncertainties related 
to phantom filling procedure are not part of this study and may increase the bandwidth of 
achievable harmonisation.
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All experiments on various PET/CT models were performed on appointed systems. The inter-
system variability stemming from the individual differences among  the systems of same make 
and differences due to manufacturer allowed variability in well counter calibration factors, 
may increase the bandwidth of achievable harmonisation even further, although the newly 
proposed harmonisation specification were set using the same bandwidth as current EARL, 
which was shown to be appropriate and feasible.
As the position of VOI-s used in the analysis and comparison of SUVmean data is based on 
PET images rather that CT data, it is to some extent affected by image noise and may induce 
a small additional uncertainty to the results. This however is reflective of the clinically used 
method of VOI positioning. When this strategy is followed, it is therefore important to also 
put a threshold on acceptable noise levels (in this paper background noise should be lower 
than 15%). Yet, use of CT based VOI definition could be of interest in order to mitigate the 
effects of noise on VOI definition and subsequently on the measurement of the recovery 
coefficients. Another alternative could be the use of SUVpeak rather than SUVmax as starting 
point for VOI definition, as was applied in Frings et al [57]. These strategies may be considered 
when developing future standards.
Current study investigated harmonisation of PET/CT systems using 18F tracer based FDG. The 
results cannot be directly transferred to system performance harmonisation involving other PET 
isotopes such as 68Ga or 82Rb which have a substantially longer positron range. System performance 
harmonisation with positron emitting isotopes other then 18F requires further investigation. 
In this feasibility study we primarily made use of reconstruction methods and parameter 
settings that were predefined or could be easily set by the user on commercially released 
systems. Where the software permitted, we applied additional reconstructions to include 
at least PSF and TOF, and also tried other reconstruction parameter settings which were 
expected to yield higher recoveries than current EARL specification. Yet, in this study we did 
not extensively explore a wide range of reconstruction settings as, e.g. iterations, subsets, 
matrix sizes etc., since our aim was to investigate clinically available protocols which are 
accessible for the users. Moreover, the investigated reconstruction modes had similar, but 
still different voxel sizes as well as the number of iterations/subsets between various systems 
which complicates direct comparison. In conclusion the harmonisation investigated in this 
study should be considered as a first feasibility test aiming at improving the current EARL 
specifications. Of course higher level of harmonisation would also be possible by considering 
more parameters, but then the question will be the feasibly in clinical practice. Further work 
is also needed to more extensively explore the impact of PSF reconstructions, voxel size and 
number of iterations/subsets on the variability of quantitative metrics of clinical datasets. 
Some reports have already been published showing that the repeatability and ICC of SUVmax, 
SUVpeak and SUVmean are at acceptable level [58].
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To conclude, despite of possible limitations, we have studied the feasibility of harmonising 
state of the art PET/CT system performances and results suggest that an update of EARL current 
specification is feasible and achievable in practice. 
3.6 Conclusions
This study investigated the feasibility of harmonising performance for PET/CT systems 
equipped with the latest Time-of-Flight (ToF) and resolution modelling (PSF) technology. 
Also, new possible specifications with higher contrast recoveries were investigated using 
various metrics such as average, maximum and peak SUV. Harmonising state of the art PET/CT 
systems with ToF and PSF technologies was found to be feasible. The harmonisation of such 
systems would require an update to the current multicentre accreditation program of EARL in 
order to accommodate higher recoveries. SUVpeak could be used as an uptake metric being 
less sensitive to noise and variation in image quality resulting from different reconstruction 
settings. It could be considered as an alternative to SUVmax if lower recoveries are considered 
to be acceptable for lesions of 17 mm diameter and smaller.
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Siemens mCT Siemens mCT Flow GE 710 Philips Ingenuity
Sensitivity 10 kcps/MBq 10.2 kcps/MBq 7.5 kcps/MBq 7.3 kcps/MBq
Peak NECR 186 kcps @ 
30.1 kBq/ml
180 kcps @ 
28 kBq/ml
130 kcps @ 
29.5 kBq/ml
124 kcps @ 
2.3 kBq/ml
TOF resolution 540 ps 540 ps N/A 540 ps
Crystal material LSO LSO Lutetium based LYSO
Crystal size 4 x 4 x 20 mm3 4 x 4 x 20 mm3 4.2 x 6.3 x 25 mm3 4 x 4 x 22 mm3
axial FOV 22.1 cm 22.1 cm 15.7 cm 18 cm
Resolution 
transverse 1cm 4.4 mm 4.3 mm 4.9 mm N/A
Resolution axial 1cm 4.4 mm 4.3 mm 5.6 mm N/A
Resolution transverse 
radial 10cm 5.7 mm 5.2 mm N/A N/A
Resolution transverse 
tangential 10cm 4.9 mm 4.7 mm N/A N/A
Axial 10 cm 5.9 mm 5.9 mm 6.3 mm N/A
Supplemental table 1. Specifications of the four PET/CT systems used for the initial 
15 reconstruction modes.
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GE 710, IQ & 
MI systems with 
Q.Clear option
GE 710, IQ 









duration (s) 300 300 300
0.5 mm/s (bed 
motion speed)
300






subsets N/A 2/24 3/33 2 / 21 3 / 21
Matrix size 256x256 256x256 144x144 200x200 400x400
Post filter N/A 5.0mm N/A Gaussian, 5.0mm Gaussian, 5.0mm
Z-filter Standard Standard N/A N/A N/A
PSF (Point 
Spread Function) ON ON ON ON ON
ToF (Time of 
Flight) ON* ON ON ON ON
Attenuation 
correction ON, CT based ON, CT based ON, CT based ON, CT based ON, CT based
Scatter 
correction ON ON ON ON ON
Supplemental table 2. Requested acquisition and reconstruction parameters during validation part 
with the 18 additional systems.
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Supplemental Fig. 4. Variable sphere size (a to i) SUVmean recovery coefficients of Siemens, 
Philips and GE reconstructions plotted as a function of background noise (CoV). Reconstructions 
determined to be suitable for harmonisation are marked with triangles of the corresponding colour.
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Supplemental Fig. 5. Variable sphere size (a to i) SUVmax recovery coefficients of Siemens, 
Philips and GE reconstructions plotted as a function of background noise (CoV). Reconstructions 
determined to be suitable for harmonisation are marked with triangles of the corresponding colour.
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Supplemental Fig. 6. Variable sphere size (a to i) SUVpeak recovery coefficients of Siemens, 
Philips and GE reconstructions plotted as a function of background noise (CoV). Reconstructions 
determined to be suitable for harmonisation are marked with triangles of the corresponding colour.
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Supplemental Fig. 7. Transversal slices from harmonising reconstructions a – Siemens 1 – D; 
b – Siemens 2 – A; c – Philips – B; d – GE – F and e – GE – E. Colour scale represents SUV values.
Supplemental Fig. 8. CoVBG values for initial 15 reconstruction modes (a) and 5 proposed 
harmonising reconstruction modes (b).
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Supplemental Fig. 9. RC curves derived from post-filtered Siemens 1 - A reconstruction using 
SUVmean (a), SUVmax (b) and SUVpeak (c) quantitative metrics along with proposed new 
EARL specifications. 
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Supplemental Fig. 10. RC curves derived from post-filtered GE - A reconstruction using 
SUVmean (a), SUVmax (b) and SUVpeak (c) quantitative metrics along with proposed new 
EARL specifications.
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Supplemental Fig. 11. RC curves derived from post-filtered Philips - A reconstruction using 
SUVmean (a), SUVmax (b) and SUVpeak (c) quantitative metrics along with proposed new 
EARL specifications. 
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4.1 Abstract
Purpose: Recently, updated EARL specifications (EARL2) have been developed and announced. 
This study aims at investigating the impact of the EARL2 specifications on the quantitative 
reads of clinical PET-CT studies and testing a method to enable the use of the EARL2 standards 
whilst still generating quantitative reads compliant with current EARL standards (EARL1).
Methods: Thirteen non-small cell lung cancer (NSCLC) and seventeen lymphoma PET-
CT studies were used to derive four image datasets – the first dataset complying with EARL1 
specifications and the second reconstructed using parameters as described in EARL2. For the 
third (EARL2F6) and fourth (EARL2F7) dataset in EARL2, respectively 6 mm and 7 mm Gaussian 
post filtering was applied. We compared the results of quantitative metrics (MATV, SUVmax, 
SUVpeak, SUVmean, TLG, tumor-to-liver and tumor-to-bloodpool ratio) obtained with these 
four datasets in 55 suspected malignant lesions using three commonly used segmentation/
volume of interest (VOI) methods (MAX41, A50P, SUV4). 
Results: We found that with EARL2 MAX41 VOI method, MATV decreases by 22%, TLG remains 
unchanged and SUV values increase by 23-30% depending on the specific metric used. The 
EARL2F7 dataset produced quantitative metrics best aligning with EARL1, with no significant 
differences between the most of the datasets (p>0.05). Different VOI methods performed 
similarly with regards to SUV metrics but differences in MATV as well as TLG were observed. No 
significant difference between NSCLC and lymphoma cancer types was observed.
Conclusions: Application of EARL2 standards can result in higher SUVs, reduced MATV 
and slightly changed TLG values relative to EARL1. Applying a Gaussian filter to PET images 
reconstructed using EARL2 parameters, successfully yielded EARL1 compliant data. 
Keywords: Performance, harmonisation, PET-CT, Quantification, EARL accreditation, standards.
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Positron emission tomography (PET) and computed tomography (CT) hybrid imaging (PET-CT) 
with 18F-fluorodeoxyglucose (18F-FDG) is widely being used in oncology for diagnosis, staging, 
restaging and therapy response evaluation due to its ability to measure metabolic changes 
[1–7]. In addition to visual inspection, quantitative PET data analysis [8] can provide additional 
benefits such as increased precision and reduced inter observer variability [9]. Standardised 
uptake value (SUV) is commonly used to represent the tissue radioactivity concentration 
normalised to the whole-body activity concentration, estimated from injected activity and 
body weight [10]. However, SUV bias and increased variability can arise from multiple factors 
[9,11] and need to be given extra consideration when multicentre data is desired or absolute 
quantitative measures used [9,12–15]. 
Therefore several scientific societies such as the European Association of Nuclear Medicine 
(EANM), American College of Radiology (ACR), American Association of Physicists in Medicine 
(AAPM), Radiological Society of North America (RSNA) and Society of Nuclear Medicine and 
Molecular Imaging (SNMMI) are promoting standardisation and harmonisation of imaging 
procedures and practices to reduce variability of quantification in a multicentre setting [16–20]. 
Results and experience with these programs are described in papers by Scheuermann et al. [19] 
Sunderland et al. [21] and Kaalep et al. [22].
In 2006, EANM Research Ltd. (EARL) initiative was launched by the EANM to promote 
multicentre nuclear medicine and research. In 2010, the EARL 18F-FDG-PET-CT accreditation 
program was established to address variability in the quickly growing field of quantitative 
18F-FDG-PET imaging by setting up guidelines and specifications to which the participating 
sites must adhere. According to these guidelines, an accredited PET-CT system, in addition to 
other requirements, has to display a SUV bias of ±10% or less and produce contrast recoveries 
within a specified bandwidth (EARL1 and EARL2), when imaging hot spheres of various sizes 
within a NEMA NU2–2007 phantom. 
The varying performance caused by multiple generations of PET-CT systems (2D, 3D 
acquisition, Time-of-Flight (TOF), etc.) and availability of various reconstruction technologies 
(e.g., resolution recovery/Point Spread Function (PSF) or Bayesian penalised-likelihood 
reconstruction) pose a particular problem when harmonisation within the community is 
desired. Multicentre standards should not be based on the least performing systems. They 
need to fit with the highest, yet common denominator in systems’ performance.
The specifications for the EARL1 18F-FDG-PET-CT accreditation program were developed during 
a pilot study performed in 2010–2011, involving 12 PET-CT systems. Since then, the performance 
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of PET-CT systems has significantly increased and new acquisition and reconstruction 
technologies have been introduced [23]. A change in technology may also unfavourably affect 
patient management when previously used quantitative and visual criteria are applied without 
adaptation to the new images [24,25]. The harmonisation of these newer systems would require 
an update of the current multicentre accreditation standards (EARL1) in order to accommodate 
higher recoveries. A phantom study by Kaalep et al. [26], showed that the harmonisation of 
modern PET-CT systems from different vendors is feasible. Based on this study, the EARL1 
specifications have been updated and EARL2 specifications were developed [26]. 
The introduction of an updated EARL standard changes quantitative PET-CT reads and these 
changes should be known and/or accounted for. Moreover, for ongoing multicenter studies 
it is advisable to continue generating data following the EARL1 standard to assure uniformity 
of image quantification for the entire multicenter dataset. The latter may be challenging 
for imaging sites as it could imply that 3 reconstructions are generated. One reconstruction 
following locally preferred settings optimised for lesion detectability, another reconstruction 
following EARL2 and a third reconstruction following EARL1 standards. Therefore, it is of 
interest to explore if an existing approach based on image filtering [27] can be applied to 
generate EARL1 compliant data from EARL2 reconstructed images. This would obviate the 
need to perform a (third) EARL1 compliant reconstruction. Moreover, it would still allow to 
generate both EARL2 and EARL1 compliant quantitative results to allow comparison of results 
with historic cohorts. Although in principle the image filtering approach can be applied to 
the clinically preferred reconstructions to generate either (or both) EARL1 or EARL2 compliant 
data, the filter settings required would vary from one site to another as locally preferred 
reconstruction settings are not the same. In a multicenter study this would require that these 
filter settings need to be derived, known and monitored for each system as this method 
does not generate EARL compliant images. Yet, deriving EARL1 compliant data from EARL2 
reconstructed images is a more standardized condition or procedure and might be more easily 
reproduced elsewhere.
The primary aim of the current study is to investigate the impact of EARL2 updated 
accreditation specifications on the quantitative reads of clinical PET-CT studies. A secondary 
objective is to evaluate the performance of an (existing) approach based on image filtering to 
generate quantitative reads that are compliant with the EARL1 standards from EARL2 compliant 
reconstructed PET images. 
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4.3 Materials and methods
4.3.1 Selecting post-filtering parameters by phantom experiments
Twenty-one phantom images from a previously described study by Kaalep et al.[26] were 
investigated. These phantom images served to determine a post filter which, when applied to 
an EARL2 compliant dataset, would result in a dataset compliant with the EARL1 standards. The 
data were collected from 17 EARL accredited scanners from major vendors – 3 Philips, 9 Siemens 
and 5 General Electric systems. The phantom experiments were performed in compliance with 
EARL Image Quality QC standard operating procedures. A NEMA NU2-2007 body phantom 
background was filled with a 2 kBq/ml 18F-FDG solution and the 10, 13, 17, 22, 28 and 37 mm 
spheres with a 20 kBq/ml 18F-FDG solution, resulting in a 10:1 sphere to background ratio when 
scanned for two 5 minute per bed positions. TOF, PSF, normalisation, randoms, scatter and 
attenuation corrections were applied. Reconstructions compliant with EARL1 as well as EARL2 
specifications were performed. Reconstructed data were analysed using a semi-automatic tool 
developed for EARL [16]. Further details regarding the acquisition of the phantom data can be 
found in the initial study [26].
An additional Gaussian post-filtering with kernel sizes of 5, 6, 7 and 8 mm respectively, 
was applied to the EARL2 compliant phantom datasets using in-house post processing and 
analysis software ACCURATE [28]. Size dependent SUVmean and SUVmax recovery coefficients 
of all resulting datasets were compared with the EARL1 accreditation specifications in order 
to determine which filter values provided the largest number of EARL1 compliant results. A 
dataset was determined to be EARL1 compliant when observed contrast recoveries of SUVmean 
and SUVmax in all spheres were within EARL1 specifications. This strategy and methodology is 
equal to the one proposed and evaluated by Lasnon et al [27] and tested here to see if it could 
also be applied to derive EARL1 compliant results from EARL2 reconstructed PET data.
4.3.2 Patient selection and preparation
Thirty patients with non-small cell lung cancer (NSCLC, n=13) or lymphoma (n=17) were 
randomly selected from ongoing routine clinical staging or restaging studies with suspected 
positive lesions. The majority of lymphoma patients were diagnosed with diffuse large B-cell 
lymphoma. A standard uptake time of 60-75 min was applied for all patients. Further details 
can be found in Table 1.
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Characteristic Non-small cell lung cancer Lymphoma Total
Total no of patients 13 17 30
Males / Females 6 / 7 10 / 7 16 / 14
Weight of patients (mean) 42 – 92 (69.4) kg 61 – 103 (78.9) kg 42 – 103 (74.8) kg
BMI of patients (mean) 18 – 28 (23.3) 19 – 41 (25.7) 18 – 41 (24.7)
Administered 
activity (mean) 161 – 314 (240) MBq 205 – 347 (274) MBq 161 – 347 (259) MBq
Total no of 
analysed lesions 19 36 55
Lesions per patient (mean) 1-3 (1.5) 1-3 (2.1) 1-3 (1.8)
Table 1. Patient characteristics.
Acquisition and reconstruction parameters
30 patient scans performed on two EARL accredited Philips Ingenuity PET-CT TOF systems 
during a period of 2.5 years (from 10.03.2016 to 10.09.2018) were selected for further analysis 
within this study. For each patient study, two PET reconstructions were performed – first, 
using the EARL1 approved reconstruction parameters resulting in contrast recoveries within 
EARL1 accreditation specifications [29], and second, using the EARL2 compliant reconstruction 
parameters proposed by Kaalep et al [26]. Two additional image datasets were generated from 
the EARL2 reconstructed images by applying Gaussian filters of 6.0 mm (EAR2F6) and 7.0 mm 
(EAR2F7), respectively. Main parameters for the four PET image datasets used in this study are 
listed in Table 2.









EARL1 4 4 BLOB-OS-TF N/A OFF
EARL2 4 4 BLOB-OS-TF N/A ON
EARL2F6 4 4 BLOB-OS-TF 6.0 ON
EARL2F7 4 4 BLOB-OS-TF 7.0 ON
Table 2. Main reconstruction parameters of the four investigated image datasets.
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4.3.3 Lesion selection, segmentation and analysis
Lesions suspected to be malignant were identified by the author (AK) and confirmed by a 
certified nuclear medicine physician with 10 years of experience reading PET-CT images (DO). 
Physiological 18F-FDG uptake (i.e. within brain, left ventricle, kidneys, urinary bladder) not 
related to the primary disease was excluded. A maximum of 3 lesions per patient was selected 
to avoid over-representation of any single patient, yielding a total of 55 lesions. VOIs were 
segmented semi-automatically using a region growing method with the following thresholds:
1. SUV ≥ 4.0 (SUV4)
2. 41% of SUVmax (41MAX)
3. 50% of SUVpeak with adaptation to local tumour-to-background contrast, 
so called adapted 50% of SUVpeak (A50P) [30]. SUVpeak is defined as the 
average uptake in a 1.2 cm diameter VOI positioned such to yield the highest 
value across all tumour voxels (also referred to as highest peak) [31].
Additionally for each patient, liver and bloodpool VOI-s were created and SUVmax, SUVpeak 
and SUVmean calculated for EARL1, EARL2 and EARL2F7 reconstructions. For assessing liver 
uptake we positioned a 3 cm diameter spherical VOI in the right upper lobe of the (healthy) 
liver, as suggested by PERCIST [31]. For the blood pool uptake a 1.5 cm spherical VOI was 
positioned in the lumen of the ascending aorta.
For each combination of lesion, reconstruction and VOI threshold, the following quantitative 
metrics were calculated: metabolic active tumour volume (MATV), SUVmean, SUVmax, SUVpeak 
and total lesion glycolysis (TLG) [30]. Moreover, we derived tumor-to-liver ratio’s using SUVmax 
of both lesion and liver as well as SUVmax of the lesion and SUVmean of the liver. Brief 
descriptions of the used VOI methods and quantitative metrics are given in Table 3.
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A50P Region growing based VOI using 50% of SUVpeak with adaptation to local tumour-to-background contrast [32][30]
SUV4 Region growing based VOI using a threshold of SUV equal to 4
MAX41 Region growing based VOI using a threshold equal to 41% of SUVmax
Quantitative Metrics Description
MATV Volume of a lesion segmented using A50P, SUV4 or MAX41 method in mL
SUVmean
Ratio of image derived average radioactivity concentration within a region of interest and the 
estimated whole body concentration of the injected radioactivity, normalised to bodyweight
SUVmax
Ratio of image derived maximum (single pixel) radioactivity concentration within a region of 
interest and the whole body concentration of the injected radioactivity, normalised to bodyweight
SUVpeak
Ratio of image derived average radioactivity concentration within a 12 mm diameter spherical 
volume (taking into account fractional voxels) within the region of interest, positioned to yield the 
highest uptake across all tumour voxel locations, and the whole body concentration of the injected 
radioactivity, normalised to bodyweight [30,31]
TLG Total lesion glycolysis equal to the MATV times SUVmean
Table 3. Descriptions of used VOI methods and quantitative metrics.
Statistical Analyses 
Median relative differences of quantitative metrics determined from EARL2, EARL2F6 and 
EARL2F7 reconstructions and corresponding values from the EARL1 reconstruction were 
reported along with interquartile ranges. Mann-Whitney U-test and Wilcoxon signed-rank test 
were used to evaluate the statistical significance of the paired and non-paired data respectively.
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Post filtering values of 6 and 7 mm resulted in the highest number of EARL2 reconstructions 
(across all phantom scans) conforming to EARL1 specifications for both SUVmean and SUVmax 
(Fig. 1) and were selected for further analysis and testing using clinical datasets. As an example, 
Fig. 2 demonstrates the investigated systems’ contrast recovery curves before and after the 
application of an additional 6 mm FWHM Gaussian post filter.
Fig. 1. Histogram of Gaussian post-filter values resulting in EARL1 compliant reconstructions of 
NEMA NU2-2007 body phantom data acquired in accordance with EARL guidelines for Image 
Quality QC standard operating procedures.
Fig. 2. Recovery coefficient values relative to sphere size determined from NEMA NU2-2007 
body phantom data acquired in accordance with EARL guidelines for Image Quality QC standard 
operating procedures. a –SUVmean of EARL2 and EARL2F6 data; b - SUVmax of EARL2 and 
EARL2F6 data. Average measured EARL1 SUV data – solid black line, average measured EARL2F6 
SUV data – solid red line current, standard deviation from average measured EARL1 SUV data – 
black dash dot dot line; standard deviation from average measured EARL2F6 SUV data – red dash 
dot dot line; EARL standard – bold black lines, prospective future EARL standard – bold red lines.
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Figure 3 illustrates an example of a malignant lesion and the associated quantitative metrics 
calculated. 
MATV EARL1 – 2,82 ml
MATV EARL2 – 2,05 ml
MATV EARL2F6 – 2,69 ml
MATV EARL2F7 – 3,07 ml
SUVmax EARL1 – 13,11
SUVmax EARL2 – 18,46
SUVmax EARL2F6 – 14,02
SUVmax EARL2F7 – 12,75
SUVpeak EARL1 – 9,36
SUVpeak EARL2 – 12,08
SUVpeak EARL2F6 – 9,84
SUVpeak EARL2F7 – 9,18
SUVmean EARL1 – 8,12
SUVmean EARL2 – 11,33
SUVmean EARL2F6 – 8,59
SUVmean EARL2F7 – 7,76
TLG EARL1 – 22,87
TLG EARL2 – 23,20
TLG EARL2F6 – 23,09
TLG EARL2F7 – 23,83
Fig. 3. Typical example image of a lymphoma patient’s 18F-FDG PET-CT scan. Coronal maximum 
intensity projection image is presented with an arrow pointing to a suspected malignant lesion 
along with the corresponding MATV, SUVmax, SUVpeak, SUVmean and TLG quantitative metrics 
determined using EARL1, EARL2, EARL2F6 and EARL2F7 reconstructions.
541106-L-bw-Kaalep
Processed on: 18-3-2020 PDF page: 106
106
CHAPTER 4
We found that EARL2 SUV data were higher than EARL1 data (p<0.001), the relative median 
difference ranging from 23% for SUVpeak to 25% for SUVmean and 30% for SUVmax (Table 4, 
Figs. 4c, 4d). The relative difference in SUV between the two datasets increased with decreasing 
MATV (p<0.001) with a median difference of 36%, 39% and 25% (SUVmax, SUVmean and 
SUVpeak, respectively) for small (< 10 ml) lesions and 22%, 21% and 15% (SUVmax, SUVmean 
and SUVpeak, respectively) for large (≥ 10 ml) lesions (Fig. 4c), with no significant dependence 
on SUVmean i.e. lesion contrast (SUVmax, p=0.162; SUVmean, p=0,225; SUVpeak, p=0,178) 
(Fig. 4d). SUV data from the filtered dataset EARL2F7 aligned best with those obtained using 
EARL1 reconstruction within -1% for SUVmax (interquartile range 9.5), -1% for SUVmean 
(interquartile range 9.4) and +2% for SUVmax (interquartile range 6.4).
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Supplemental Fig. 4. Relative differences of 41MAX VOI method EARL2 and EARL2F7 
reconstructions’ MATV, SUVmax and TLG metrics compared to respective values from EARL1 
reconstruction, presented as functions of EARL1 MATV and SUVmean. EARL2 reconstruction – 
red markers, EARL2F7 reconstruction – blue markers.
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MATV seen on the EARL2 were on average 27% smaller (p<0.001) when compared to EARL1 
(Table 4, Figs. 4a, 4b), while the difference reduced to a statistically non-significant +2% 
(p=0.547) when EARL2F7 and EARL1 were compared. The relative difference in EARL2 and 
EARL1 MATV values was found to be dependent on the underlying MATV values (p<0.001) with 
an average difference of -31% for small (< 10 ml) lesions and -19% for large (≥ 10 ml) lesions 
(Fig. 4a). Significant MATV dependence (p<0.001) remained when EARL2F7 and EARL1 were 
compared, with a median difference of +6% for small (< 10 ml) lesions and -8% for large (≥ 10 
ml) lesions. A significant dependence of underlying SUV levels (p=0.033) was found in MATV 
differences of EARL2 and EARL1, where lesions with SUVmean ≤ 7.0 demonstrated a median 
difference of -29% while lesions with SUVmean > 7.0 demonstrated a median difference of 
-20%. Differences in MATV of EARL2F7 to EARL1 were independent (p=0.076) on underlying 
SUV levels (Fig. 4b).
We found a statistically significant (p=0.005) difference of -2% in median TLG values of EARL1 
and EARL2 while no statistically significant difference in TLG derived from EARL1 and EARL2F7 
(p=0.744) or EARL1 and EARL2F6 (p=0.815). 
Figure 5 demonstrates the differences in SUV in liver and bloodpool VOIs between EARL1 
and EARL2 and EARL2F7 reconstructions. The largest difference can be seen with SUVmax 
while SUVmean demonstrates the smallest change. Figure 6 visualises tumor-to-liver ratio’s 
calculated using various combinations of SUV metrics.
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Supplemental Fig. 5. Relative differences of 41MAX VOI method EARL2 and EARL2F7 
reconstructions’ liver and blood pool SUVmean, SUVmax and SUVpeak metrics compared to 
respective values from EARL1 reconstruction, presented as functions of EARL1 SUVmean. 
EARL2 reconstruction – red markers, EARL2F7 reconstruction – blue markers. 
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Supplemental Fig. 6. Relative differences of 41MAX VOI method EARL2 and EARL2F7 
reconstructions’ tumor-to-liver ratios compared to respective values from EARL1 reconstruction, 
presented as functions of EARL1 MATV and SUVmean. a – tumor SUVmax to liver SUVmax ratio 
relative to MATV; b – tumor SUVmax to liver SUVmax ratio relative to SUVmean; c – tumor 
SUVmax to liver SUVmean ratio relative to MATV; d – tumor SUVmax to liver SUVmean ratio 
relative to SUVmean; e – tumor SUVpeak to liver SUVpeak ratio relative to MATV; f – tumor 
SUVpeak to liver SUVpeak ratio relative to SUVmean; g – tumor SUVmean to liver SUVmean 
ratio relative to MATV; h – tumor SUVmean to liver SUVmean ratio relative to SUVmean; EARL2 
reconstruction – red markers, EARL2F7 reconstruction – blue markers.
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Tumor-to-liver ratio was significantly higher for EARL2 when either SUVmax (p<0.001) or 
SUVmean (p<0.001) were used to measure liver SUV (Table 4). For EARL2F7 the difference with 
EARL1 data was still statistically significant (p<0.001) when SUVmax was used to measure liver 
SUV and non-significant (p=0.344) when liver SUVmean was used. All investigated metrics 
changed similarly between EARL2, EARL2F6 and EARL2F7 reconstructions regardless of cancer 
type (Fig. 7). SUVmax and SUVpeak metric changes remained similar while SUVmean, MATV and 
TLG behaviour differed based on the VOI method used (Supplemental Fig. 8). These differences 
between VOI methods were eliminated in the EARL2F7 reconstruction (Supplemental Fig. 8). 
Cancer type Reconstruction MATV SUVmax SUVpeak SUVmean TLG
Tumor 
SUVmax







EARL_V2 -22* (18) 30* (13) 23* (11) 25* (18) -1 (8) 18* (10) 29* (12)
EARL_V2F6 0 (8) 3* (6) 5* (3) 3* (5) 2 (5) N/A N/A
EARL_V2F7 9 (13) -3 (8) 1 (7) -2 (7) 4 (12) 6* (9) -3 (8)
Lymphoma
EARL_V2 -28* (18) 35* (18) 24* (12) 37* (19) -3* (10) 26* (16) 35* (19)
EARL_V2F6 -7* (12) 6* (11) 6* (7) 6* (12) 0 (8) N/A N/A
EARL_V2F7 0 (13) 0 (9) 2 (6) 0 (9) 0 (10) 6* (7) 0 (9)
Both 
combined
EARL_V2 -27* (16) 33* (18) 23* (12) 34* (18) -2* (8) 22* (15) 34* (17)
EARL_V2F6 -5* (12) 5* (11) 5* (5) 5* (8) 1 (7) N/A N/A
EARL_V2F7 2 (16) -1 (10) 2* (6) -1 (9) 2 (11) 6* (8) 1 (9)
Table 4. MAX41 VOI method relative median differences (%) of MATV, SUV metrics and TLG to 
corresponding values of EARL1 reconstruction along with corresponding interquartile ranges. 
Values marked with * indicate that the difference is statistically significant (p < 0.05).
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Fig. 7. Comparison of relative differences of MATV (a), SUVmax (b), SUVmean (c), SUVpeak (d), 
TLG (e) and tumor-to-liver ratio (tumor SUVmax relative to liver SUVmean) (f) metrics between 
EARL1 and EARL2, EARL2F6, and EARL2F7 reconstructions, respectively, using 41MAX VOI 
method. Results obtained from lung cancer and lymphoma patients are presented separately. 
Central line of the box is the median, edges of the box are the 25th and 75th percentiles, 
the whiskers extend to either of the most extreme data points, which are not considered outliers 
or 1.5 times interquartile range. The outliers are marked using plus signs.
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Application of the updated EARL2 standards will affect quantitative reads. Yet, an update 
of the current EARL1 standards is required to cope with new PET-CT technologies providing 
enhanced lesion detectability. In this paper we studied the impact of using EARL2 standards 
on the quantitative reads of NSCLC and lymphoma 18F-FDG PET-CT studies as compared to the 
EARL1 standards. An (existing) image filtering approach that enables the use of updated EARL2 
compliant reconstruction, whilst still generating EARL1 compliant quantitative reads was 
derived and tested. The latter is important to allow comparison of data during ongoing studies 
and/or for comparison with historical cohorts.
As previously shown in the phantom study by Kaalep et al. [26], EARL2 compliant reconstruction 
resulted in a significant increase in contrast recovery and higher SUVs. The current study confirms 
these findings for clinical data (table 4) and demonstrates that overall trends (table 4, Fig. 7) were 
similar for both lung cancer and lymphoma patients, despite different lesion sizes and tracer 
uptake levels (or SUV). This suggests that the results of the current study could be universally 
applicable regardless of underlying disease type but this should be further investigated in future 
studies covering a wider range of patients and conditions. 
Increase in contrast in EARL2 compliant reconstructions is similar for the most common used 
metrics SUVmax and SUVpeak applying all investigated VOI methods (Supplemental Fig. 8) and is 
independent of the lesion contrast (SUVmean). However, the results demonstrate a dependence 
on lesion volume where smaller lesions show a larger increase in contrast. The overall increased 
contrast recovery explains the wider and generally more preferred use of PSF reconstructions [23].
EARL2 compliant reconstructions result in a significant reduction in MATV values when MAX41 
VOI method is used. Small (< 10 ml) lesions demonstrate a relatively higher decrease in volume 
than larger (≥ 10 ml) lesions. At the same time smaller lesions demonstrate larger increase in all 
SUV metrics which could be explained by the improved resolution and reduced spill-out effect 
caused by the PSF reconstruction. Post-filtering of the EARL2F6 and EARL2F7 reconstructions 
mimics the spill-out effect as the image is blurred by the filter resulting in loss of resolution and 
dispersion of measured activity in a larger volume. These results should not be transferred to other 
VOI methods as the PSF reconstruction affects different lesion segmentation methods differently.
TLG did not change significantly among the four investigated reconstructions. This may 
have been expected since while the lesion contrast (SUVmean) increases, MATV decreases 
proportionally, resulting in a reduced change in the product of the two. This reconstruction-
independent behaviour of TLG could potentially make it a good metric for generating consistent 
quantitative measurements from both EARL1 and EARL2 standards without further image 
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modification. This is in agreement with Armstrong et al., who suggested that TLG may be less 
sensitive to reconstruction methods compared with either SUVmax or SUVpeak [33]. TLG could 
also reduce the uncertainty of quantitative measurements of PET-CT scans that are performed 
on a system with unknown recovery coefficients. These results should not be transferred to 
SUV4 VOI methods as the PSF reconstruction affects the different lesion segmentations and 
therefore the corresponding TLG values also.
EARL1 compliant quantitative results can be generated from EARL2 reconstructed data 
using a simple filter. This approach has been applied and validated before by Lasnon et al., 
specifically for PSF reconstruction on a Siemens Biograph PET-CT system using the so-called 
EQ.PET approach [27]. The method could however be considered limited due to lack of similar 
solutions by other major vendors. Moreover, the appropriate filter for each PET-CT system is 
not reported in the DICOM header and thereby the method cannot be applied offline or by 
3rd party software. In our paper we identified (from phantom experiments) and verified the 
appropriate Gaussian filter setting in order to use EARL2 compliant reconstructions, while 
enabling the generation of EARL1 quantitative results. Also, it is important for verification of 
new datasets to be equivalent with historical cohorts. In this way data can be easily generated 
to conform both EARL1 and EARL2 standards without a need for additional reconstructions. 
For ongoing studies, however, it is recommended to keep adherence to the EARL1 standard 
and optionally adding EARL2 compliant reconstructions to gain understanding of quantitative 
implications when transitioning to the new standard.
It has been demonstrated by Kuhnert et al. that the increase in SUV, brought on by the use of 
PSF reconstruction, remains significant even after normalisation to the liver [24]. In our study, 
we also found that normalising lesion uptake to either liver SUVmax or liver SUVmean resulted 
in significantly increased tumor-to-liver ratio’s and confirm the results from Kuhnert et al that 
normalizing to liver uptake does not mitigate the effect of using different reconstructions 
on lesion uptake assessments. Apart from harmonizing quantitative 18F-FDG PET-CT reads, 
it has been reported that also visual assessment, e.g. Deauville scoring of PET-CT lymphoma 
studies, may be affected by a change in (reconstruction) technology and could affect patient 
management [25]. The observed changes (increases) in tumor-to-liver ratio’s for EARL2 versus 
EARL1 compliant data suggest that use of EARL2 standards will result in overall higher Deauville 
scores, similarly as recently found by Ly et al.[34]. Therefore, it is not recommended to change 
standards and/or use new technologies without properly (re-)defining interpretation criteria. 
Hence use of EARL2 compliant reconstruction in combination with generating a second filtered 
dataset could be helpful in recalibrating these criteria for studies performed conform EARL1 
performance standards to those obtained using updated performance standards. However, it 
should be noted that although this filtering approach has been shown to yield EARL1 compliant 
results and may facilitate these type of studies, this has not yet been demonstrated in this study 
nor was the aim.
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Multicentre clinical trials require standardisation of quantitative results in order to be usable 
and exchangeable. This can be challenging as new acquisition and reconstruction technologies 
emerge and enable great benefits in image quality, but at the same time cause the quantitative 
performance to diverge. 
In this paper we studied the impact of using updated EARL2 standards on the quantitative 
reads of NSCLC and lymphoma 18F-FDG PET-CT studies as compared to the EARL1 standards. 
In general, the new EARL2 guidelines resulted in higher SUVs, smaller MATV and similar TLG 
values. A 7 mm FWHM Gaussian filter was shown to convert EARL2 compliant PET data to EARL1 
compliant images. This facilitates the generation of both new and existing EARL compliant 
quantitative reads from a single EARL2 compliant image reconstruction.
4.7 Declarations
4.7.1 Abbreviations
NSCLC: non-small cell lung cancer; VOI: volume of interest; PET: positron emission tomography; 
CT: computed tomography; 18F-FDG: 18F-fluorodeoxyglucose; SUV: standardised uptake value; 
EANM: European Association of Nuclear Medicine; ACR: American College of Radiology; AAPM: 
American Association of Physicists in Medicine; RSNA: Radiological Society of North America; 
SNMMI: Society of Nuclear Medicine and Molecular Imaging; EARL: EANM Research Ltd.; TOF: time-
of-flight; PSF: point spread function; BMI: body mass index; A50P: region growing based VOI using 
50% of SUVpeak with adaptation to local tumour-to-background contrast; SUV4: region growing 
based VOI using a threshold of SUV equal to 4; MAX41: region growing based VOI using a threshold 
equal to 41% of SUVmax; MATV: volume of a lesion segmented using A50P, SUV4 or MAX41 method 
in mL; SUVmean: ratio of image derived average radioactivity concentration within a region of 
interest and the estimated whole body concentration of the injected radioactivity, normalised to 
bodyweight; SUVmax: ratio of image derived maximum (single pixel) radioactivity concentration 
within a region of interest and the whole body concentration of the injected radioactivity, 
normalised to bodyweight; SUVpeak: ratio of image derived average radioactivity concentration 
within a 12 mm diameter spherical volume within the region of interest, positioned to yield the 
highest uptake, and the whole body concentration of the injected radioactivity, normalised to 
bodyweight; TLG: total lesion glycolysis equal to the MATV times SUVmean.
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4.7.2 Ethical Approval and Consent to participate
This retrospective study was approved by the Institutional Medical Ethics Committee (case 
number VUMC 2018.029), and the need for informed consent was waived. Consultation of the 
local objection registry verified that none of the selected patients had objected to use of their 
personal data for research purposes.
4.7.3 Consent for publication
Not applicable
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Supplemental Fig. 8. Comparison of relative differences of MATV (a), SUVmax (b), SUVmean 
(c), SUVpeak (d), TLG (e) and tumor-to-liver ratio (tumor SUVmax relative to liver SUVmean) 
(f) metrics between EARL1 and EARL2, EARL2F6, and EARL2F7 reconstructions, respectively, 
using different VOI methods. Central line of the box is the median, edges of the box are the 25th 
and 75th percentiles, the whiskers extend to either of the most extreme data points, which are not 
considered outliers or 1.5 times interquartile range. The outliers are marked using plus signs.
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Supplemental Fig. 9. Relative differences of A50P VOI method EARL2 and EARL_V2F7 
reconstructions’ MATV, SUVmax and TLG metrics compared to respective values from EARL1 
reconstruction, presented as functions of EARL1 MATV and SUVmean. EARL2 reconstruction
 – red markers, EARL2F7 reconstruction – blue markers.
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Supplemental Fig. 10. Relative differences of SUV4 VOI method EARL2 and EARL2F7 
reconstructions’ MATV, SUVmax and TLG metrics compared to respective values from EARL1 
reconstruction, presented as functions of EARL1 MATV and SUVmean. EARL2 reconstruction 
– red markers, EARL2F7 reconstruction – blue markers.
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Supplemental Fig. 11. Relative differences of 41MAX VOI method EARL2 and EARL2F7 
reconstructions’ tumor-to-bloodpool ratio compared to respective values from EARL1 
reconstruction, presented as functions of EARL1 MATV and SUVmean. a – tumor SUVmax to 
bloodpool SUVmax ratio relative to MATV; b – tumor SUVmax to bloodpool SUVmax ratio relative 
to SUVmean; c – tumor SUVmax to bloodpool SUVmean ratio relative to MATV; d – tumor 
SUVmax to bloodpool SUVmean ratio relative to SUVmean; e – tumor SUVpeak to bloodpool 
SUVpeak ratio relative to MATV; f – tumor SUVpeak to bloodpool SUVpeak ratio relative to 
SUVmean; g – tumor SUVmean to bloodpool SUVmean ratio relative to MATV; h – tumor 
SUVmean to bloodpool SUVmean ratio relative to SUVmean; EARL2 reconstruction – red markers, 
EARL2F7 reconstruction – blue markers
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Purpose: The aim of this study was to investigate the variability in quantitative performance 
and feasibility of quantitative harmonisation in 89Zr PET/CT imaging.
Methods: Eight EANM EARL accredited [1] PET/CT systems were investigated using phantom 
acquisitions of uniform and NEMA NU2-2007 body phantoms. The phantoms were filled 
according to EANM EARL guidelines for [18F]FDG but [18F]FDG solution was replaced by a 89Zr 
calibration mixture. For each system, standard uptake value (SUV) accuracy and recovery 
coefficients (RC) using SUVmean, SUVmax and SUVpeak metrics were determined. 
Results: All eight investigated systems demonstrated similarly shaped RC curves and five 
of them exhibited closely aligning recoveries when SUV bias correction was applied. From 
the evaluated metrics, SUVpeak was found to be least sensitive to noise and reconstruction 
differences among different systems.
Conclusions: Harmonisation of PET/CT scanners for quantitative 89Zr studies is feasible 
when proper scanner -dose calibrator cross-calibration and harmonised image reconstruction 
procedures are followed. An accreditation program for PET/CT scanners would facilitate 
multi-centre 89Zr quantitative studies.
541106-L-bw-Kaalep




The use of radiolabeled antibodies for diagnostic and therapeutic purposes has been going on 
for more than 50 years [2]. Their application as imaging probes in positron emission tomography 
(PET) combines the high sensitivity of PET with the high antigen specificity of monoclonal 
antibodies [3]. 89Zr based tracers are becoming widespread with increasingly available supply, 
advances in radiochemistry and successful pilot studies in humans. However, multicentre studies 
using 18F labelled tracers have demonstrated the need for standardisation of image acquisition, 
reconstruction, and analysis procedures and international harmonisation programs such as 
EANM and EARL aim to facilitate the use of FDG PET as a quantitative imaging biomarker [1,4]. 
A detailed discussion on 89Zr physics in PET has been published by Conti et al [5].
The aim of this study was to investigate the variability in quantitative performance and 
feasibility of quantitative harmonisation in 89Zr PET/CT imaging.
5.3 Materials and methods
5.3.1 Investigated systems & phantom experiments
Eight PET/CT systems (system 1 - 8), calibrated according to manufacturer’s instructions, while 
also participating and accredited in the EANM/EARL [18F]FDG PET/CT accreditation program, 
were selected for this study. The investigated systems were two General Electric Discovery 690; 
two General Electric Discovery 710; one Siemens Biograph 40 mCT; one Siemens Biograph 64 
mCT; one Siemens Somatom Definition AS mCT and one Philips Ingenuity TF.
Two phantom experiments were carried out in accordance with EANM/EARL guidelines – 
Calibration QC and NEMA Phantom QC, where [18F]FDG was substituted with a 89Zr calibration 
sample. In the first experiment, a uniform cylindrical phantom was filled with a solution 
containing 8-12 kBq/mL of 89Zr. In the second experiment the NEMA NU2-2007 body phantom 
background compartment and spheres were filled with a 89Zrsolution of 2 kBq/mL and 20 kBq/
mL respectively, so as a 10:1 sphere to background ratio be achieved (Figure 1). Exact amount 
of 89Zr activity was measured for each scan using only local dose calibrators, which had not 
underwent specific cross-calibration for 89Zr. In both experiments the phantoms underwent 
a low-dose CT acquisition followed by PET acquisition of two consecutive bed positions of 
5 minutes each. Images were reconstructed using EARL compliant parameters routinely used 
by the corresponding sites for [18F]FDG quantitative imaging (Table 1).
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A Discovery 690 3.65 3.27 VPFXS 6.4 Yes
B Discovery 690 2.73 3.27 VPHD 6.5 No
C Discovery 710 2.73 3.27 VPFX 6.4 No
D Discovery 710 2.73 3.27 VPFXS 9.0 Yes
E Biograph 40 mCT 3.18 2.00 PSF+TOF 7.0 Yes
F Somatom Definition 
AS mCT
3.18 5.00 PSF+TOF 8.0 Yes
G Ingenuity TF PET/CT 4.00 4.00 BLOB-OS-TF 4.0 No
H Biograph 64 mCT 4.07 5.00 OSEM3D+TOF 5.0 No
Table 1. Reconstruction settings 
Fig. 1. versal slice of 89Zr filled NEMA NU2-2007 body phantom
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Reconstructed DICOM images were analysed using the EARL semi-automatic tool 
[1,6] designed for quantitative analysis of images of uniform and NEMA NU2-2007 body 
phantoms. From the uniform phantom and the NEMA body phantom’s uniform background 
compartment, SUV accuracies for each system were determined. From the NEMA body 
phantom experiments, recovery coefficients (RC) were calculated as a function of sphere sizes, 
defined as ratio of activity concentration estimated from PET images to the expected activity 
concentration measured by dose calibrator. Different RC metrics values were calculated based 
on 50% background corrected isocontour VOI (SUVmean), maximum voxel value included 
in VOI (SUVmax) and spherical VOI with a diameter of 12 mm, positioned so as to yield the 
highest uptake (SUVpeak) [6][7][8]. Using data from the EARL database, relevant FDG RC curves 
of the corresponding scanners are displayed as a reference.
Additionally, RC curves were rescaled to correct for a global SUV bias, derived from the 
phantom’s background compartment, to mitigate the impact of cross-calibration error 
between PET/CT system and dose calibrator on the observed RC. In order to directly compare 
the RC curves’ shapes of all systems, the individual recovery coefficients of the NEMA body 
phantom spheres were normalised to the recovery coefficient of the largest (37 mm) sphere.
5.4 Results
The SUV bias from both phantom experiments are presented in Figure 2. The results for 
SUVmean, SUVmax and SUVpeak together with corresponding information for EARL [18F]FDG 
can be seen in Figure 3, while the results corrected for SUV bias calculated from the body 
phantom background, are presented in Figure 4. Figure 5 demonstrates the RC curves 
normalised to the largest 37 mm sphere recovery.
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Fig. 2. SUV accuracy of the PET scanners relative to the dose calibrator measurements plotted 
by system number. Systems 1-2 and 3-4 represent GE scanners Discovery 690 and Discovery 
710, respectively; systems 5-6 are Siemens Biograph 40_mCT and Somatom Definition AS_mCT; 
system 7 is the Philips Ingenuity TF PET/CT; system 8 is the Siemens Biograph 64_mCT.
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Fig. 3. RC curves derived from the 89Zr phantom experiments using SUVmean (a), SUVmax (b) and 
SUVpeak (c) quantitative metrics and corresponding RC curves derived from the EARL [18F]FDG 
phantom experiments using SUVmean (d), SUVmax (e) and SUVpeak (f) quantitative metrics. 
Current EARL specifications for [18F]FDG-PET/CT accreditation are presented as bold dashed 
lines. Systems 1-2 and 3-4 represent GE scanners Discovery 690 and Discovery 710, respectively; 
systems 5-6 are Siemens Biograph 40_mCT and Somatom Definition AS_mCT; system 7 is the 
Philips Ingenuity TF PET/CT; system 8 is the Siemens Biograph 64_mCT.
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Fig. 4. Background SUV bias corrected RC curves derived from the phantom experiments using 
SUVmean (a), SUVmax (b) and SUVpeak (c) quantitative metrics. Current EARL specifications for 
[18F]FDG-PET/CT accreditation are presented as bold dashed lines. Systems 1-2 and 3-4 represent 
GE scanners Discovery 690 and Discovery 710, respectively; systems 5-6 are Siemens Biograph 
40_mCT and Somatom Definition AS_mCT; system 7 is the Philips Ingenuity TF PET/CT; system 8 
is the Siemens Biograph 64_mCT.
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Fig. 5. RC curves normalised to the largest sphere, derived from the phantom experiments using 
SUVmean (a), SUVmax (b) and SUVpeak (c) quantitative metrics. Systems 1-2 and 3-4 represent 
GE scanners Discovery 690 and Discovery 710, respectively; systems 5-6 are Siemens Biograph 
40_mCT and Somatom Definition AS_mCT; system 7 is the Philips Ingenuity TF PET/CT; system 8 
is the Siemens Biograph 64_mCT.
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5.5 Discussion
In order to remain in the optimal measurement range of the dose calibrators, the 89Zr activity 
used in the study was similar to what is injected to a patient in clinical practice, resulting in 
significantly higher activity concentrations in  the phantoms compared to patients (due to 
the smaller phantom volumes). However, lower counts are expected to further increase the 
variability of the results and may have hampered comparing recoveries between systems, with 
current EARL specifications and with those seen with 18F. For clinical studies low count rates 
potentially induce an upward bias when SUVmax is used. To mitigate this upward bias, SUVpeak 
is an alternative less sensitive to scanner variation and image noise and might therefore be 
the optimal metric to assess tracer uptake for 89Zr. Consequently, in our phantom study we 
included SUVpeak as well.
In addition to verifying the results of a recent study by Makris et al [9], current study 
investigated the real life scenario of using only local dose calibrators for 89Zr measurement 
as well as by asking sites to perform the experiments themselves using the provided manuals 
and instructions. Out of the eight systems investigated in total, four Calibration QC and three 
NEMA Phantom QC experiments demonstrate a SUV bias of >10% (Figure 2). Since the scanners 
are EARL accredited for [18F]FDG-PET/CT, they comply with accreditation specifications for SUV 
bias (≤ 10%), it is therefore believed that the large global errors are due to inaccurate cross-
calibration between the scanners and dose calibrators used to measure the 89Zr solution 
activity on site. While each of the dose calibrators should be set up by the manufacturer to 
accurately measure 89Zr, the results from our study underline the importance of a traceable 
calibration performance of dose calibrators used in 89Zr quantitative PET/CT imaging.
From Figure 2, it can be seen that SUV bias values derived from Calibration QC and NEMA 
Phantom QC background agree reasonably well, with the exception of only system 3 and to 
some extent system 4. These inconsistencies as well as the variable bias in RC curves (Figure 3) 
are suggested to be related to activity measurement and phantom filling procedures on site.
The initial RC curves derived from the images (Figure 3, a-c) demonstrate increased spread 
compared to the background corrected ones (Figure 4). After applying the SUV bias correction, the 
RC values of five systems show good alignment with each other and with EANM specifications for 
[18F]FDG. Two of the investigated systems (1 and 7) remain out of specifications even after correcting 
for SUV bias. The reason for this is unknown and would need further investigation. RC curves 
normalised to the largest (37 mm) sphere (Figure 5) demonstrate similar shapes of RC curves for 
all investigated systems. This would suggest that, with further adjustment – meaning reduction of 
global SUV bias based on Calibration QC experiment data and possibly minor adjustment of the 
image reconstruction parameters – all of the systems should be able to achieve harmonisation.
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The closest alignment of the RC curves can be observed when SUVpeak is used. This 
demonstrates the potential of this metric being used when quantitative harmonisation is 
desired. It should however be noted that with the use of SUVpeak, one should expect a decrease 
in overall contrast recovery, compared to SUVmax.
Finally, with the shape of 89Zr RC curves shown to be similar to 18F in our pilot study, further 
harmonisation efforts could be focused on the cross-calibration of the dose calibrators, which 
is considered to be the largest source of uncertainty in this case. A future 89Zr harmonisation 
scheme could therefore be based on a 89Zr dose calibrator cross-calibration quality control, 
with a successful site [18F]FDG EARL accreditation being a prerequisite.
5.6 Conclusions
All eight investigated systems demonstrated similarly shaped RC curves and five of them 
exhibited close alignment when SUV bias correction was applied. Use of SUVpeak as a metric, 
which proved to be least sensitive to noise and reconstruction differences among systems, 
is strongly recommended for multicentre quantitative 89Zr studies. When PET/CT and dose 
calibrator cross-calibration procedures are closely followed and the image reconstruction 
parameters adjusted, the quantitative harmonisation of scanners for 89Zr PET studies is 
feasible. Yet, our results demonstrate the urgent need to set up a suitable cross-calibration and 
accreditation program to facilitate multi-centre 89Zr quantitative studies.
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A sensible future direction for any quantitative multicentre accreditation would be the 
extension of existing quality control regimens beyond the widely used [18F]FDG to include 
emerging novel isotopes and tracers. The application of 68Ga is increasing because of affordable 
production by using a 68Ge/68Ga generator and the possibility to label both small compounds 
and macromolecules [1]. Due to their slower pharmacokinetics, using monoclonal antibodies as 
therapeutic target-specific agents has generated interest in radioisotopes with longer half-lives, 
such as 64Cu, 76Br, 89Y, 89Zr and 124I [2][3][4]. These have also demonstrated potential in theranostics - 
molecular imaging in tandem with a therapeutic agent, which could be either pharmaceutical or 
radiotherapeutic. Imaging with these isotopes however brings new challenges to quantification 
such as emitted and scattered prompt gammas within the energy window of the PET scanner, 
high energy gammas with associated pair production and high energy positrons escaping patient, 
among others [5]. Quantification of pure positron emitters such as 89Zr is relatively simple and 
possibly could be tied to an existing 18F quantification scheme. In this way, if the PET scanners 
are harmonised for 18F, then further harmonisation to 89Zr would require minimal additional 
efforts – possibly in the form of an additional global scanner calibration control. Quantification 
of 76Br, 86Y, 82Rb and 124I is more complicated since the random coincidences from prompt gamma 
contamination could blur or add a non-uniform background to the images. In the case of non-
pure positron emitters, the feasibility of quantification depends on better randoms or prompt 
gamma correction methods to be developed by the PET system vendors. 
Future research into advancing quantitative PET imaging will involve the review, extension of 
existing and inclusion of additional quality control metrics and tools to further improve the accuracy 
and consistency of quantitative reads. As PET systems advance, the accuracy of activity concentration 
estimation increases. This will facilitate for state-of art PET devices the application of more strict 
accreditation and standardisation criteria than currently in place, but, as a result some of the older 
systems will not  comply with the more stringent requirements [6]. Additional quality control tools 
are under development, which may include the use of image derived quality metrics – extraction of 
quality metrics directly and preferably seamlessly from routine clinical studies [7,8]. For instance, 
general scanner calibration could be checked by evaluating the total amount of activity detected 
within the study field of view. This however requires further investigation into tracer distributions 
in clinical studies and the development and validation of a quality control tools for this purpose.
Standardisation programs for various imaging tasks and modalities such as quantitative 
brain imaging of Alzheimer’s patients, gated cardiac PET or PET/MR could be devised to take 
into account the specific technical and task related features of possible failure and therefore 
tailor quality metrics and ways of standardisation in order to reduce the quantitative variability 
among different imaging sites and various imaging systems.
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Recently, whole‐body parametric PET imaging has become a reality, allowing to generate 
full quantitative parametric images for the whole body [9]. A discussion is ongoing on whether 
this will replace or be added to the commonly performed procedure of multibed acquisitions, 
resulting in a static PET image from where conventional semi‐quantitative image‐derived PET 
metrics, such as the Standardized Uptake Value (SUV), are then derived and used in the context 
of clinical oncology [10]. Using Patlak analysis, the acquisition of functional parameters such 
as metabolic rate might even be achieved by making only two static late scans while the input 
function can be measured directly from PET images. Additional investigation is required to 
determine the accuracy and repeatability of quantitative data obtained by this method and 
whether the current standardisation programs will suffice for whole body dynamic PET 
investigations or new dedicated schemes will have to be developed.
Emergence of total body PET systems, i.e. systems with extended axial field of view (up to 2 
m) such as in the EXPLORER PET/CT project, opens up new possibilities, but, poses difficulties 
as well, regarding the quality control procedures for such devices. Quality control phantoms 
currently in use cannot cover the entire field of view of a whole body scanner, which is a 
prerequisite in many quality control measurements. Therefore, either a longer phantom has 
to be developed or a technique worked out on how a shorter phantom is to be moved through 
the scanners field of view and account for each axial location of the system.
Radiomics is another rapidly developing field which provides large amounts of quantitative 
data based on image features such as texture, surface, shape and position of objects, 
surrounding tissue among many others, which may uncover disease characteristics unseen by 
conventional review of images [11][12]. These data are extracted from images using specific 
data characterisation algorithms which themselves may require further standardisation of 
more specific image quality features not in the attention of the human reader. It may also 
require the development of specific non-spherical and/or heterogeneous phantom inserts to 
measure radiomics features using more realistic tumour uptake distributions from those that 
currently can be achieved using the typical spherical and uniform inserts [13].
Finally, artificial intelligence (AI) and machine learning is rapidly making its way to nuclear 
medicine as well as to other kinds of medical imaging. AI can mine data (including image data) 
for patterns and anomalies and then use them to make predictions and recommendations to 
the reporting physician [14]. Further research is required to assess how much consistency in 
images is required for AI to work most effectively and the need for harmonisation programs 
specifically designed to facilitate AI applications. However, at present this field is still fully in 
development and it is too early to provide recommendations at this stage. Yet, initial studies 
show that standardisation of the imaging procedures and equipment performances are 
needed for using radiomics/AI analysis in multicentre studies as well [15].
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In recent years PET has become a widespread functional and quantitative imaging tool. Due 
to its quantitative nature and being widely used in multicentre trials, it is essential to have 
quality assurance and quality control procedures in place to ensure the accuracy and precision 
of quantitation. In this thesis, the experience and results of running a large scale EANM-EARL 
[18F]FDG PET/CT accreditation program is described and analysed. An update, taking into 
account the latest advances in PET/CT systems such as time-of-flight and resolution modelling, 
to the existing EARL accreditation criteria is investigated and developed. The impact of the 
newly developed and updated EARL harmonising program on quantitative reads of clinical 
PET/CT studies is investigated and a method enabling the use of updated standards while still 
generating quantitative reads, compliant with existing EARL standards, is tested. Additionally, 
in order to explore the possibility to expand the accreditation program to additional tracers, 
the feasibility of 89Zr PET/CT quantitative harmonisation is demonstrated.
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CHAPTER 7
In recent years positron emission tomography has become a widespread functional imaging 
tool used for diagnosing, staging and restaging of various malignancies. As a quantitative imaging 
method, it is mandatory to have quality assurance and quality control procedures in place so as 
to ensure the accuracy and precision of quantitation. Additionally, the number of multicentre 
trials involving PET, where the requirement is to have uniform quantitative performance across 
all PET/CT systems, increases and quantitative evaluation and endpoints are more frequently 
used [1][2]. A particular problem to uniform quantitative imaging is posed by different levels 
of technology in imaging centres [3]. This requires the standardisation of imaging procedures 
and harmonisation of PET/CT system performance to achieve proper multicentre performance. 
EANM-EARL is running a PET/CT accreditation program which aims at facilitating multicentre 
studies based on the EANM Guidelines [4] for standardisation of [18F]FDG PET/CT imaging and is 
harmonising the system performances by applying a self-developed procedure. 
Chapter 2 describes the six years’ experience of running the EANM-EARL [18F]FDG PET/CT 
accreditation programme based on the first set of EARL standards and reports the findings and 
impact on the harmonised PET/CT systems. During the reported period, more than 2500 quality 
control datasets were collected from 200 systems in 150 imaging sites worldwide. Over the 
course of their accreditation period, each participating centre was requested to submit scans 
of two different phantoms - calibration quality control (CalQC), using a uniform cylindrical 
phantom and image quality control (IQQC), using the NEMA NU2–2007 body phantom. 
Average volumetric SUV bias and SUV recovery coefficients (RC) were calculated by EARL using a 
semi-automatic analysis program, then the data evaluated on the basis of quality control type, 
approval status, PET/CT system manufacturer and submission order. It was shown that SUV 
bias in 5% (n = 96) of all CalQC submissions (n = 1816) exceeded the acceptance level (10%). After 
corrective actions following communication of the results, the accredited sites achieved 100% 
compliance with EARL specifications. 30% (n = 1381) of SUVmean and 23% (n = 1095) of SUVmax 
sphere recoveries from first IQQC submissions failed to meet EARL accreditation criteria. After 
harmonisation of the scanners, for the subsequent submissions the failure rate decreased 
to 12% (n = 360) and 9% (n = 254), respectively. Most systems demonstrated longitudinal 
SUV bias reproducibility within ±5%, while RC values remained stable and generally within 
±10% for the four largest and ±20% for the two smallest spheres. It can be concluded that 
regardless of manufacturer or model, all investigated systems were able to comply with the 
EARL specifications. Within the EARL accreditation program, gross PET/CT calibration errors 
are successfully identified and longitudinal variability in PET/CT performances reduced. The 
program demonstrates that a harmonising accreditation procedure is feasible and achievable.
Based on the standardisation experience, Chapter 3 explores the possibility of modernising 
EARL FDG accreditation programme by harmonising the performance of state of the art PET/CT 
systems equipped with time-of-flight (ToF) and resolution modelling/point spread function 
(PSF) technologies. Additionally, a method helping the new harmonising criteria with 
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higher contrast recoveries to comply with current EARL standards using various SUV metrics is 
developed. For the experiment, four PET/CT systems with both ToF and PSF capabilities from 
three major vendors were used. NEMA NU2–2007 body phantom scans were acquired and 
analysed using the EANM-EARL accreditation procedures. A total of 15 reconstruction parameter 
sets of varying pixel size, post filtering and reconstruction type, with three different acquisition 
times were used to compare the quantitative performance of the systems. A target range for 
recovery curves was established which accommodated the highest matching recoveries from all 
investigated systems. These updated criteria were validated on 18 additional scanners from 16 
EARL accredited sites in order to demonstrate the scanners’ ability to meet the new target range. 
Each of the four systems was found to be capable of producing harmonising reconstructions 
with similar recovery curves. The reconstruction parameter sets producing harmonising 
results, significantly increased SUVmean (25%) and SUVmax (26%) contrast recoveries compared 
with current EARL specifications. The additional prospective validation performed on 18 
scanners from 16 EARL accredited sites demonstrated the feasibility of updated harmonising 
specifications. SUVpeak was found to significantly reduce the variability in quantitative results 
while producing lower recoveries in smaller (≤17 mm diameter) sphere sizes. Harmonising PET/
CT systems with ToF and PSF technologies from different vendors was found to be feasible. 
The harmonisation of such systems would require an update of the current multicentre EARL 
accreditation program in order to accommodate higher recoveries. SUVpeak should be further 
investigated as a noise resistant alternative quantitative metric to SUVmax.
In Chapter 4 the impact of the newly developed and updated EARL harmonising criteria on 
quantitative reads of clinical PET/CT studies is investigated and a method enabling the use of 
updated standards, while still generating quantitative reads compliant with existing EARL 
standards, is tested. To this end, thirteen non-small cell lung cancer (NSCLC) and seventeen 
lymphoma PET/CT studies were used to derive four image datasets – the first dataset (EARL1) 
complying with existing EARL specifications and the second (EARL2) reconstructed using 
parameters complying with new proposed EARL specifications. For the third (EARL2F6) and 
fourth (EARL2F7) datasets, respectively 6 mm and 7 mm Gaussian post filtering was applied to 
the EARL2 dataset. We compared the results of quantitative metrics (MATV, SUVmax, SUVpeak, 
SUVmean, TLG) obtained with these four datasets in 55 suspected malignant lesions using three 
commonly used segmentation/volume of interest (VOI) methods (MAX41, A50P, SUV4). It was 
found that with EARL2 MAX41 VOI method, MATV decreases by 25%, TLG remains unchanged 
and SUV values increase by 23-32% depending on the specific metric used. The EARL2F7 dataset 
produced quantitative metrics best aligning with EARL1, with no significant differences between 
the datasets (p>0.05). Different VOI methods performed similarly with regards to SUV metrics 
but differences in MATV as well as TLG were observed. No significant difference between NSCLC 
and lymphoma cancer types was observed. Application of EARL2 standards can result in higher 
SUVs, reduced MATV and unchanged TLG values relative to EARL1. Applying a Gaussian filter to 
PET images reconstructed using EARL2 parameters, successfully yielded EARL1 compliant data.
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Chapter 5 expands beyond FDG and investigates the variability in quantitative performance 
and feasibility of quantitative harmonisation in 89Zr PET/CT imaging. Eight EANM-EARL PET/CT 
systems accredited for [18F]FDG were investigated using scans from uniform and NEMA NU2-
2007 body phantoms. The phantoms were filled conform to the EANM-EARL accreditation 
specifications for [18F]FDG but the [18F]FDG solution was replaced by an 89Zr calibration mixture. 
For each system, standard uptake value (SUV) accuracy and recovery coefficients (RC) using 
SUVmean, SUVmax and SUVpeak metrics were determined. All eight investigated systems 
demonstrated similarly shaped RC curves and five of them exhibited closely aligning recoveries 
when SUV bias correction was applied. From the evaluated metrics, SUVpeak was found to be 
the least sensitive to noise and reconstruction differences among different systems. It can be 
concluded that harmonisation of PET/CT scanners for quantitative 89Zr studies is feasible when 
proper scanner to activity meter cross-calibration and harmonised image reconstruction 
procedures are followed. An accreditation program for 89Zr PET/CT imaging would facilitate 
multi-centre 89Zr quantitative studies.
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Positron emissie tomografie (PET) is de laatste jaren een wijdverspreide functionele medisch 
beeldvormende techniek geworden voor de diagnose, stadiëring en her-stadiëring van 
verschillende maligniteiten. Voor het gebruik als kwantitatieve techniek is het noodzakelijk 
een kwaliteitssysteem te hebben voor de borging en controle van de nauwkeurigheid en 
precisie van de kwantitatieve resultaten. Bovendien neemt het aantal multicenter onderzoeken 
waarbinnen kwantitatieve PET wordt toegepast toe. Kwantitatieve evaluatie en kwantitatieve 
eindpunten worden steeds vaker toegepast, waarbij een uniforme basis voor harmonisatie van 
kwantitatieve resultaten een voorwaarde is [1][2]. De aanwezigheid van verschillende niveaus 
met betrekking tot de stand der techniek tussen de verschillende participerende instituten 
vormt een uitdaging voor het verkrijgen van uniforme en vergelijkbare resultaten [3]. EANM-
EARL is een PET/CT accreditatie programma met het doel om multicenter studies te faciliteren 
door standaardisering, via de EANM Guidelines [4], van protocollen en de harmonisatie van de 
kwantitatieve prestaties van de gebruikte PET/CT systemen. 
Hoofdstuk 2 beschrijft de zes jaar ervaring met het uitvoeren van het EANM-EARL [18F] 
FDG PET/CT accreditatieprogramma op basis van de eerste set EARL normen en rapporteert 
de bevindingen en impact daarvan op de kwantitatieve prestaties van de geharmoniseerde 
PET/CT systemen. Tijdens de gerapporteerde periode werden meer dan 2500 datasets voor 
kwaliteitscontrole verzameld van 200 systemen op 150 locaties wereldwijd. In de loop van hun 
accreditatieperiode werd elk deelnemend centrum verzocht om scans van twee verschillende 
fantomen in te dienen: kalibratie-kwaliteitscontrole (CalQC), met behulp van een uniform 
cilindrisch fantoom, en beeld-kwaliteitscontrole (IQQC), met behulp van het NEMA NU2–2007 
fantoom. De gemiddelde SUV afwijking en SUV recoverycoëfficiënten (RC) werden berekend 
door EARL met behulp van een semi-automatisch analyseprogramma en vervolgens werden 
de gegevens geëvalueerd op basis van het soort kwaliteitscontrole, goedkeuringsstatus, PET/
CT fabrikant en indieningsvolgorde. Er werd aangetoond dat de SUV afwijking in 5% (n = 96) 
van alle CalQC-inzendingen (n = 1816) het acceptatieniveau (10%) overschreed. Na corrigerende 
maatregelen na mededeling van de resultaten, waren 100% van de geaccrediteerde sites in 
staat te voldoen aan de EARL specificaties. Verder was gevonden dat 30% (n = 1381) van de 
gemiddelde SUV waarden en 23% (n = 1095) van maximale SUV waarden voor de bollen in het 
NEMA fantoom van eerste IQQC inzendingen niet voldeden aan de EARL accreditatiecriteria. 
Na harmonisatie van de scanners daalde het aantal afwijkingen voor de daarvop volgende 
inzendingen tot respectievelijk 12% (n = 360) en 9% (n = 254). De meeste systemen vertoonden 
een lange termijn SUV voorspelbaarheid binnen ± 5%, terwijl RC waarden in het algemeen 
stabiel bleven binnen ± 10% voor de vier grootste en ± 20% voor de twee kleinste bollen. 
Geconcludeerd kan worden dat, ongeacht de fabrikant of het model van de PET/CT camera, 
alle onderzochte systemen konden voldoen aan de EARL specificaties. Binnen het EARL 
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accreditatieprogramma worden grove PET/CT kalibratiefouten met succes geïdentificeerd en 
lange termijn variabiliteit in PET/CT prestaties verminderd. Het programma toont aan dat een 
harmoniserende accreditatieprocedure haalbaar is.
Gebaseerd op de ervaring met standaardisatie, wordt hoofdstuk 3 het onderzoek 
beschreven naar de mogelijkheid om het EARL FDG accreditatieprogramma te moderniseren 
door de prestaties van geavanceerde PET/CT systemen, uitgerust met time-of-flight (ToF) en/of 
resolutiemodellering / point spread-functie (PSF) technologieën, te harmoniseren. Bovendien 
is een methode ontwikkeld die de nieuwe harmonisatiecriteria voor SUV met hogere recovery 
waarden helpt te voldoen aan de huidige EARL normen. Voor het experiment werden vier 
PET/CT systemen met zowel ToF als PSF mogelijkheden van drie grote leveranciers gebruikt. 
Scans van het NEMA NU2–2007 fantoom werden verkregen en geanalyseerd met behulp 
van de EANM-EARL accreditatieprocedures. Een totaal van 15 reconstructieparametersets 
met variërende pixelgrootte, filtering en reconstructiealgoritme en met drie verschillende 
acquisitietijden werden gebruikt om de kwantitatieve prestaties van de systemen te vergelijken. 
Een doelbereik voor recovery curves werd vastgesteld zodanig dat deze overeenkomst tussen 
resultaten maximaliseerde. Deze bijgewerkte criteria werden gevalideerd op 18 extra scanners 
van 16 EARL geaccrediteerde sites om aan te tonen dat de scanners in staat zijn om aan het 
nieuwe doelbereik te voldoen. Elk van de vier systemen bleek in staat te zijn data te produceren 
met vergelijkbare recovery curves. De nieuw reconstructieparametersets produceren 
harmoniserende resultaten met aanzienlijk hogere SUVmean (25%) en SUVmax (26%) 
recoveries in vergelijking met de huidige EARL specificaties. De aanvullende prospectieve 
validatie uitgevoerd op 18 scanners van 16 EARL geaccrediteerde sites toonde de haalbaarheid 
aan van de bijgewerkte specificaties. SUVpeak bleek de variabiliteit in kwantitatieve resultaten 
aanzienlijk te verminderen en tegelijkertijd lagere recovery te produceren in kleinere (≤17 
mm diameter) bollen. Harmonisatie van PET/CT systemen met ToF en PSF technologieën 
van verschillende leveranciers bleek haalbaar. De harmonisatie van dergelijke systemen zou 
een update van het huidige multicenter EARL accreditatieprogramma vereisen om hogere 
SUV recoveries mogelijk te maken. SUVpeak moet verder worden onderzocht als een meer 
ruisbestendig alternatieve kwantitatieve maat in plaats van SUVmax.
In hoofdstuk 4 wordt de impact van de nieuw ontwikkelde en bijgewerkte EARL 
harmonisatiecriteria op kwantitatieve metingen van klinische PET/CT onderzoeken bestudeerd 
en wordt een methode getest die het gebruik van de bijgewerkte normen mogelijk maakt, 
terwijl nog steeds kwantitatieve metingen worden gegenereerd die voldoen aan bestaande 
EARL normen. Daartoe werden dertien niet-kleincellige longkanker (NSCLC) en zeventien 
lymfoom PET/CT onderzoeken gebruikt om vier beelddatasets af te leiden - de eerste dataset 
(EARL1) die voldoet aan de bestaande EARL-specificaties en de tweede (EARL2) gereconstrueerd 
met behulp van parameters die voldoen aan de nieuwe voorgestelde EARL specificaties. Voor 
de derde (EARL2F6) en vierde (EARL2F7) gegevenssets werd respectievelijk 6 mm en 7 mm 
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Gaussische postfiltering toegepast op de EARL2 PET beelden. We vergeleken de resultaten van 
kwantitatieve maten (MATV, SUVmax, SUVpeak, SUVmean, TLG) verkregen met deze vier datasets 
van 55 vermoedelijke kwaadaardige laesies met behulp van drie veelgebruikte segmentatie / 
volume of interest (VOI) methoden (MAX41, A50P, SUV4). Het bleek dat met de EARL2 MAX41 
VOI methode de MATV met 25% afneemt, de TLG ongewijzigd blijft en de SUV-waarden met 
23-32% stijgen, afhankelijk van de gebruikte maat. De EARL2F7 dataset produceerde kwantitatieve 
resultaten die het beste overeenkomen met EARL1, zonder significante verschillen tussen de 
datasets (p> 0,05). Verschillende VOI methoden presteerden vergelijkbaar met betrekking tot 
de diverse bekeken SUV maten, maar verschillen in zowel MATV als TLG werden waargenomen. 
Er werd geen significant verschil tussen NSCLC- en lymfoomkankertypen waargenomen. 
Toepassing van EARL2 normen kan leiden tot hogere SUV’s, lager MATV en ongewijzigde 
TLG waarden ten opzichte van EARL1. Het toepassen van een Gaussisch filter op PET beelden 
gereconstrueerd met behulp van EARL2 parameters, leverde gegevens op die overeenkwamen 
met die verkregen met EARL1 parameters.
Hoofdstuk 5 gaat verder dan FDG en onderzoekt de variabiliteit in kwantitatieve prestaties 
en haalbaarheid van kwantitatieve harmonisatie in PET/CT beeldvorming met 89Zr. Acht EANM-
EARL PET/CT systemen geaccrediteerd voor [18F]FDG werden onderzocht met behulp van scans 
van het uniforme en het NEMA NU2-2007 fantoom. De fantomen werden gevuld conform de 
EANM-EARL accreditatiespecificaties voor [18F]FDG maar de [18F]FDG oplossing werd vervangen 
door een kalibratiemengsel van 89Zr. Voor elk systeem werden de standaard uptake value 
(SUV) nauwkeurigheid en recoverycoëfficiënten (RC) met behulp van SUVmean, SUVmax en 
SUVpeak bepaald. Alle acht onderzochte systemen vertoonden gelijke RC curves en vijf van 
hen vertoonden dicht bij elkaar liggende recoveries wanneer SUV afwijkingscorrectie werd 
toegepast. Uit de geëvalueerde meetwaarden bleek SUVpeak het minst gevoelig voor ruis- en 
reconstructieverschillen tussen verschillende systemen. Geconcludeerd kan worden dat een 
harmonisatie van PET/CT systemen voor kwantitatieve 89Zr onderzoeken haalbaar is wanneer 
de juiste kruiskalibratie van scanner, dosiskalibrator wordt uitgevoerd en geharmoniseerde 
beeldreconstructieprocedures worden gevolgd. Een accreditatieprogramma voor 89Zr PET/CT 
beeldvorming zou multicenter 89Zr kwantitatieve studies vergemakkelijken.
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